Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
- LUCEY DANIEL R ET AL: "Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases." CLINICAL MICROBIOLOGY REVIEWS, vol. 9, no. 4, 1996, pages 532-562, XP002241521 ISSN: 0893-8512
- KIENY M P ET AL: "ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS ENV PROTEIN EXPRESSED FROM A RECOMBINANT VACCINIA VIRUS" BIO-TECHNOLOGY (NEW YORK), vol. 4, no. 9, 1986, pages 790-795, XP009011051 ISSN: 0733-222X
Inadequate antigen presentation in humans results in the failure of the human immune system to control and clear many pathogenic infections and malignant cell growth. Successful therapeutic vaccines and immunotherapies for chronic infection and cancer rely on the development of new approaches for efficient antigen presentation to induce a vigorous immune response which is capable of controlling and clearing the offensive antigens.

A crucial step in mounting an immune response in mammals is the activation of CD4+ helper T-cells that recognize major histocompatibility complexes (MHC)-II restricted exogenous antigens. These antigens are captured and processed in the cellular endosomal pathway in antigen-presenting cells, such as dendritic cells (DCs) (Zajac et al., 1998; Bona et al., 1998; Kalams et al., 1998; Mellman et al., 1998; Banchereau et al., 1998). In the endosome and lysosome, the antigen is processed into small antigenic peptides that are presented onto the MHC-II proteins. This requirement to recognize an antigen in association with a self-MHC protein is called MHC restriction. MHC-II proteins are found on the surface of virtually all nucleated cells. MHC-II proteins are found on the surface of certain cells including macrophages, B cells, and dendritic cells of the spleen and Langerhans cells of the skin.

A crucial step in mounting an immune response in mammals is the activation of CD4+ helper T-cells that recognize major histocompatibility complexes (MHC)-II restricted exogenous antigens. These antigens are captured and processed in the cellular endosomal pathway in antigen-presenting cells, such as dendritic cells (DCs) (Zajac et al., 1998; Bona et al., 1998; Kalams et al., 1998; Mellman et al., 1998; Banchereau et al., 1998). In the endosome and lysosome, the antigen is processed into small antigenic peptides that are presented onto the MHC-II in the Golgi compartment to form an antigen-MHC-II complex. This complex is expressed on the cell surface, which expression induces the activation of CD4+ T-cells.

Upon activation, CD4+ T-cells (helper T cells) produce interleukins. These interleukins help activate the other arms of the immune system. For example, helper T cells produce interleukin-4 (IL-4) and interleukin-5 (IL-5), which help B cells produce antibodies; interleukin-2 (IL-2), which activates CD4+ and CD8+ T-cells; and gamma interferon, which activates macrophages.

Since helper T-cells that recognize MHC-II restricted antigens play a central role in the activation and clonal expansion of cytotoxic T-cells, macrophages, natural killer cells, and B cells, the initial event of activating the helper T cells in response to an antigen is crucial for the induction of an effective immune response directed against that antigen. Attempts to stimulate helper T-cell activation using a sequence derived from the lysosomal membrane proteins have been reported (Wu, 1995). However, these attempts did not result in the induction of effective immune responses with respect to CD8+ T-cells and B cells in the mammals being tested.

SUMMARY OF THE INVENTION

An embodiment of the present invention is an expression vector comprising a polynucleotide promoter se-
In other specific embodiments said polynucleotide promoter sequence is selected from the group consisting of a constitutive promoter, an inducible promoter and a tissue specific promoter.

In other specific embodiments said constitutive promoter is selected from the group consisting of a simian virus 40 (SV40) early promoter, a mouse mammary tumor virus promoter, a human immunodeficiency virus long terminal repeat promoter, a Moloney virus promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, a human actin promoter, a human myosin promoter, a human hemoglobin promoter, cytomegalovirus (CMV) promoter and a human muscle creatine promoter.

In other specific embodiments said inducible promoter is selected from the group consisting of a metallothionine promoter, cytomegalovirus (CMV) promoter and a human muscle creatine promoter.

In other specific embodiments said tissue specific promoter is selected from the group consisting of HER-2 promoter and a PSA associated promoter.

In other specific embodiments said polynucleotide encoding a signal sequence is selected from the group consisting of a hepatitis B virus E antigen signal sequence, an immunoglobulin heavy chain leader sequence, and a cytokine leader sequence.

In other specific embodiments said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a B cell response in a mammal.

In other specific embodiments said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a CD4+ T-cell response in a mammal.

In other specific embodiments said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a CD8+ T-cell response in a mammal.

In other specific embodiments said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a CD8+ T-cell response in a mammal.

In other specific embodiments said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a B cell response, a CD4+ T-cell response, and a CD8+ T-cell response in a mammal into which said antigen is introduced.

In other specific embodiments said polynucleotide encoding an antigen comprises a polynucleotide sequence for a plurality of epitopes, wherein said plurality of epitopes induces a B cell response, a CD4+ T-cell response, and a CD8+ T-cell response in a mammal into which said antigen is introduced.

In other specific embodiments said polynucleotide encoding a cell binding element is a homologous Fc fragment.

In other specific embodiments said polynucleotide encoding a cell binding element is a heterologous Fc fragment.

In other specific embodiments said expression vector further comprises an integration signal sequence which facilitates integration of said expression vector into the genome of the cell.

In preferred embodiments the integration signal sequence is a viral long terminal repeat sequence or an adeno-associated virus ITR sequence.

In other specific embodiments the vector is selected from the group consisting of viral vector, bacterial vector and mammalian vector.

The present invention also provides an isolated transformed cell comprising an expression vector of the present invention, wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence, all operatively linked.

In specific embodiments said cell is prokaryotic or eukaryotic.

In other specific embodiments said eukaryotic cell is selected from the group of eukaryotic cells consisting of yeast, insect, and mammalian cells.

The present invention also provides a fusion protein encoded by the expression vector of the present invention.

The present invention also provides a vaccine comprising an expression vector of the present invention and a vaccine comprising antigen presenting cells, wherein said antigen presenting cells are transduced in vitro with the fusion protein of the present invention.

The present invention also provides a vaccine comprising antigen presenting cells, wherein said antigen presenting cells are transduced in vitro with the expression vector of the present invention; and a vaccine comprising the fusion protein of the present invention.

In another embodiment the present invention provides the use of an expression vector of the present invention, for the preparation of a medicament for eliciting an immune response directed against said antigen, wherein said expression vector is for introduction into a cell, and wherein said cell will express said vector to produce said antigen under conditions, wherein said antigen is secreted from the cell; said secreted antigen is endocytosed into the cell; said
endocytosed antigen is processed inside the cell; and said processed antigen is presented to a cell surface protein, to elicit a T-cell mediated immune response.

[0035] In particular embodiments the processed antigen is presented to a cell surface protein selected from the group consisting of MHC-I, MHC-II or B-cells receptors.

[0036] In particular embodiments the antigen is secreted by a first cell and internalized by a second cell.

[0037] In particular embodiments the first cell and second cell are antigen presenting cells.

[0038] In particular embodiments the first cell is a non-antigen presenting cell and the second cell is an antigen presenting cell.

[0039] In particular embodiments the first cell is a muscle cell.

[0040] The present invention also provides the use of an expression vector of the present invention for the preparation of a medicament for eliciting, an immune response directed against an antigen in a mammal, wherein the medicament is for direct administration to said mammal via a parenteral route.

[0041] The present invention also provides a method to identify a polynucleotide sequence which encodes at least one MHC-II restricted epitope that is capable of activating CD4+ helper T cells, said method comprising the steps of:

introducing \textit{in vitro} an expression vector of any of the present invention, in which the polynucleotide encoding an antigen is replaced by a polynucleotide that is not known to elicit an immune response, into an antigen presenting cell

contacting said transduced antigen presenting cell with naive T-cells or primed T-cells; and

assessing whether any naive T-cells or primed T-cells are activated upon contact with said transduced antigen presenting cell wherein activation of said T cells indicates that the polynucleotide encoding the test polypeptide is a gene or fragment thereof, which encodes at least one MHC-II restricted epitope that is capable of activating CD4+ helper T cells.

[0042] In preferred embodiments the polynucleotide encoding a test polypeptide is a cDNA library isolated from tumor cell lines.

[0043] In preferred embodiments the polynucleotide encoding a test polypeptide is selected from the group of cDNA libraries consisting of viral genomes, bacterial genomes, parasitic genomes, and human genomes.

[0044] The present invention also provides a method to identify a polynucleotide sequence which encodes at least one MHC-II restricted epitope that is capable of eliciting an immune response \textit{in vivo}, said method comprising the steps of:

collecting T-cells from splenocytes from a mammal to which a transduced antigen presenting cell had been administered via a parenteral route, wherein the transduced antigen presenting cell had been produced by introducing an expression vector of any of the present invention, in which the polynucleotide encoding an antigen is replaced by a polynucleotide that is not known to elicit an immune response, into antigen presenting cells \textit{in vitro}, and co-culturing said T-cells with dendritic cells; and

assessing activation of T-cells wherein said activation of T-cells indicates that the polynucleotide encoding the test polypeptide is a polynucleotide sequence or fragment thereof, which encodes at least one MHC-11 restricted epitope that is capable of activating CD4+ helper T cells.

[0045] The present invention also provides a method to identify a polynucleotide sequence which encodes at least one MHC-II restricted epitope that is capable of eliciting an immune response \textit{in vivo}, said method comprising the steps of:

collecting T-cells from splenocytes from a mammal to which an expression vector of the present invention, in which the polynucleotide encoding an antigen is replaced by a polynucleotide that is not known to elicit an immune response, had been administered via a parenteral route and co-culturing said T-cells with dendritic cells; and

assessing activation of T-cells wherein said activation of T-cells indicate that the polynucleotide encoding the test polypeptide is a polynucleotide sequence or fragment thereof, which encodes at least one MHC-11 restricted epitope that is capable of activating CD4+ helper T cells.

[0046] In preferred embodiments the polynucleotide encoding a test polypeptide is a cDNA library isolated from tumor cell lines.

[0047] In preferred embodiments the polynucleotide encoding a test polypeptide is selected from the group of cDNA libraries consisting of viral genomes, bacterial genomes, parasitic genomes, and human genomes.

[0048] The present invention also provides a method of producing a vaccine to immunize a mammal comprising the
transducing antigen presenting cells \textit{in vitro} by introducing an expression vector of any of the present invention into said antigen presenting cells to produce a transduced antigen presenting cell, all operatively linked; and

expressing said vector to produce an antigen under conditions wherein said antigen is secreted from the cell.

[0049] The present invention also provides the use of a vaccine of the present invention for transducing antigen presenting cells \textit{in vitro}.

[0050] The present invention also provides the use of a cytokine expression vector and a retrogen expression vector of the present invention for the preparation of a medicament for inducing an immune response in a mammal.

[0051] In specific embodiments the cytokine expression vector contains the sequence for GM-CSF.

[0052] In specific embodiments the cytokine expression vector contains the sequence for IL-2.

[0053] The present invention also provides the use of an expression vector for the preparation of a medicament for inducing an immune response in a mammal, wherein said expression vector comprises a polynucleotide sequence encoding a cytokine protein and a polynucleotide sequence encoding a fusion protein of the present invention under transcriptional control of one Promoter.

[0054] The present invention also provides the use of an expression vector of the present invention for the preparation of a medicament for inducing an immune response in a mammal comprising a polynucleotide sequence encoding a cytokine protein and a polynucleotide sequence encoding a fusion protein of the present invention, which are under separate transcriptional control, and wherein the polynucleotide sequence encoding the cytokine protein and the polynucleotide sequence encoding the fusion protein are in tandem in the one expression vector.

[0055] The present invention also provides the use of two different retrogen expression vectors for the preparation of a medicament for inducing an immune response in a mammal, wherein the first and the second retrogen expression vector are independent vectors according to the present invention.

[0056] The present invention also provides the use of an expression vector for the preparation of a medicament for inducing an immune response in a mammal, wherein said expression vector comprises a polynucleotide sequence encoding a first fusion protein of the present invention and a polynucleotide sequence encoding a second fusion protein of the present invention under transcriptional control of one promoter, wherein said first fusion protein comprises a first Signal sequence, a first antigen and a first cell binding element, which is an Fc fragment and said second fusion protein comprises a second Signal sequence, a second antigen and a second cell binding element, which is an Fc fragment.

[0057] In preferred embodiments said first and second Signal sequences are the same Signal sequence, first and second antigens are different antigens and said first and second cell binding elements are the same cell binding element.

[0058] In preferred embodiments said first and second Signal sequences are different Signal sequences, first and second antigens are different antigens and said first and second cell binding elements are the same cell binding element.

[0059] In preferred embodiments said first and second Signal sequences are the same Signal sequence, first and second antigens are different antigens and said first and second cell binding elements are different cell binding elements.

[0060] In preferred embodiments said first and second Signal sequences are different Signal sequences, first and second antigens are different antigens, and said first and second cell binding elements are different cell binding elements.

[0061] In preferred embodiments the polynucleotide sequence encoding the first fusion protein and the polynucleotide sequence encoding the second fusion protein are under separate transcriptional control, and wherein the polynucleotide sequence encoding the first fusion protein and the polynucleotide sequence encoding the second fusion protein are in tandem in one expression vector.

[0062] The present invention also provides the use of a fusion protein of the present invention for the preparation of a medicament for simultaneously inducing both CD4+ and CD8+ T-cells, wherein the protein comprises both a MHC-I and MHC-II epitope fused to a cell binding element.

[0063] The present invention also provides a method of producing a fusion protein comprising the steps of:

transducing an antigen presenting cell by introducing an expression vector of any of the present invention into said antigen presenting cell to produce a transduced antigen presenting cell and

expressing said vector to produce a fusion protein under conditions, wherein said fusion protein is secreted from the cell.

[0064] The present invention also provides the use of the fusion protein of the present invention for the preparation of a medicament for the treatment of a mammal, wherein the antigen presenting cells are transduced with the fusion protein \textit{in vitro} prior to the administration of the medicament to said mammal.

[0065] The present invention also provides the use of the fusion protein of the present invention for the preparation
of a medicament for the treatment of a mammal, wherein the fusion protein is to be administered parenterally to said mammal.

[0066] The present invention also provides a method of secreting an intracellular protein comprising the steps of:

introducing an expression vector of any of the present invention into a cell in vitro, and

expressing said vector to produce a fusion protein under conditions, wherein said fusion protein is secreted from the cell.

[0067] In specific embodiments a region of said polynucleotide encoding an intracellular protein is truncated to increase the efficiency of secretion.

[0068] In specific embodiments a region of said polynucleotide encoding an intracellular protein is mutated to increase the efficiency of secretion.

[0069] In specific embodiments said polynucleotide encoding an intracellular protein is not a hepatitis B virus E antigen or a cancer antigen, which is MAGE-3, but HPV 16 E7.

[0070] The present invention also provides a method of secreting a membrane protein comprising the steps of:

introducing an expression vector of the present invention into a cell in vitro, and

expressing said vector to produce a fusion protein under conditions, wherein said fusion protein is secreted from the cell.

[0071] In preferred embodiments a region of said polynucleotide encoding a membrane protein is truncated to increase the efficiency of secretion.

[0072] In preferred embodiments a region of said polynucleotide encoding a membrane protein is mutated to increase the efficiency of secretion.

[0073] In preferred embodiments said polynucleotide encoding a membrane protein is not a hepatitis B virus E antigen or a cancer antigen, which is MAGE-3, but EBV nuclear antigen 1.

[0074] Another specific embodiment of the present invention is a method of secreting a membrane protein comprising the steps of introducing an expression vector into a cell, wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding a membrane protein, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence, all operatively linked and expressing said vector to produce a fusion protein under conditions wherein said fusion protein is secreted from the cell. More specifically, the polynucleotide sequence encoding the membrane protein is truncated or mutated to increase efficiency of secretion.

BRIEF DESCRIPTION OF THE DRAWINGS

[0075] Figure 1A and Figure 1B are diagrams representing the retrogen strategy of the invention. The retrogen of the invention is produced in a cell, for example, a muscle cell (Figure 1A), and is then taken up by an antigen presenting cell (Figure 1B). The retrogen is processed in the antigen presenting cell and is expressed thereon as a MHC-I or a MHC-II complex, or presented to B cell receptors as shown in the Figure 1A and Figure 1B. MHC-I presentation of the retrogen results in the activation of cytotoxic CD8+ T-cells and MHC-II presentation of the retrogen results in the activation of CD4+ T-cells.

Figure 2A, Figure 2B and Figure 2C are a series of schematic representations of the expression vectors. Figure 2A illustrates a vector comprising HBeAg (secretory), HBcAg (cytosolic), or the Fc fragment with a signal sequence (secretory) constructed by generating a fusion gene as shown in the diagram, and cloning the gene into the retroviral vector (LNC-NGFR) or the expression vector pRc/CMV. Figure 2B and Figure 2C illustrate additional vectors that were constructed.

Figure 3 is an image of a Western blot depicting expression and secretion of the HBe-retrogen. COS cells were transfected with various expression vectors. The culture medium (M) and cell lysates (C) were then precipitated with an anti-IgG or anti-HbeAg antibody and analyzed by SDS-PAGE.

Figure 4A, Figure 4B and Figure 4C are a series of graphs depicting transduction and expression of retrogen in
dendritic cells. Murine bone marrow cells were transduced with various recombinant retroviral vectors; the cells were matured into dendritic cells in the presence of GM-CSF, TNF, and IL-4 and stained with the anti-NGFR. They are measured by a flow cytometric assay. Figure 4A shows the untransduced dendritic cells. Figure 4B shows the transduced dendritic cells. Figure 4C is a negative control.

Figure 5A, Figure 5B, Figure 5C, Figure 5D and Figure 5E are a series of graphs depicting the presence of surface markers (MHC-I, MHC-II, co-stimulation, and adhesion molecules (CD11C, CD54, CD80 and CD86)) on dendritic cells as determined by flow cytometric assays. Figure 5A shows the presence of CD11C surface marker. Figure 5B shows the presence of CD54 surface marker. Figure 5C shows the presence of CD80 surface marker. Figure 5D shows the presence of CD86 surface marker. And Figure 5E shows the, presence of MHC-II.

Figure 6A and Figure 6B illustrate two bar graphs depicting in vitro activation of naive CD4+ T-cells by retrogen-transduced dendritic cells. Figure 6A shows levels of GM-CSF in co-culture. Figure 6B shows the levels of IFN-γ in the co-culture medium.

Figure 7A and Figure 7B illustrate the MHC-II-dependent activation. Figure 7A shows the cytokine concentration (IFN-γ) from cells obtained from MHC-II-knockout (KO) or wild-type (WT) C57BL/6 mice transduced with the HBe-retrogen and co-cultured and naive CD4+ T-cells from wild type mice. Figure 7B shows the GM-CSF cytokine concentration.

Figure 8 shows antibody responses in the sera of immunized mice.

Figure 9A, Figure 9B, Figure 9C, Figure 9D, Figure 9E and Figure 9F show the construction and expression of S-MAGE-3-Fc fusion proteins. Figure 9A shows the schematic representation of recombinant retroviral vectors. (S: the signal sequence. IRES: Internal ribosome entry site sequence.) Figure 9B shows the expression of different constructs in dendritic cells as determined by Western blot analysis stained with the mouse anti-MAGE-3 and an anti-mouse IgG HRP conjugate. Figure 9C shows the protein band intensity of the Western blot of Figure 9B analyzed by a PhosphorImager (Molecular Dynamics) with an Image-Quant software. Figure 9D, Figure 9E and Figure 9F illustrate the flow cytometric analysis of transduced dendritic cells transduced with each construct and stained for MHC-II (Figure 9E) (M5/114.15.2), CD40 (Figure 9D) (HM40-3), and CD86B7.2 (Figure 9F) (GL1) (PharMingen).

Figure 10A, Figure 10B, Figure 10C and Figure 10D show the in vivo induction of CD4+ Th1 responses of mice immunized with dendritic cells transduced with different vectors in the media after co-culture of CD4+ T-cells. Figure 10A shows the concentrations of TNF-α. Figure 10B shows the concentrations of IL-2. Figure 10C shows the concentrations of TNF-α. Figure 10D shows the concentrations of IL-4.

Figure 11A and Figure 11B show the IFN-γ levels in CD4+ T-cells isolated from s-MAGE-3-Fc-dendritic cells immunized mice co-cultured with s-MAGE-3-Fc-dendritic cells in the presence or absence of anti-CD4 or anti-CD8 antibodies (Figure 11 A), or co-cultured with HBCAg transduced dendritic cells (Figure 11B).

Figure 12A, Figure 12B, Figure 12C and Figure 12D show the cytokine levels in CD4+ T-cells isolated from pooled splenocytes of mice immunized with dendritic cells co-cultured with dendritic cells isolated from draining lymph nodes (LN) of the same immunized mice at a ratio of 1000:1. Figure 12A shows the concentrations of IFN-γ. Figure 12B shows the concentrations of IL-2. Figure 12C shows the concentrations of TNF-α. Figure 12D shows the concentrations of IL-4.

Figure 13 shows the in vivo induction of cytotoxicity responses from splenocytes isolated from immunized mice which were re-stimulated (E) in vitro with irradiated EL4-MAGE-3 cells and co-cultured with the 3H-thymidine labeled target cells, EL4-MAGE-3 or EL4-HBCAg (control) (T).

Figure 14 shows the induction of antibody responses 6 weeks after dendritic cell immunization.

Figure 15 shows the enhanced interaction of T-cells with s-MAGE-3-Fc-dendritic cells by measuring the IL-12 levels in the co-culture in the presence or absence of an anti-CD40L antibody (MR1, PharMingen) measured by ELISA.

Figure 16A and Figure 16B show the antitumor immunity of mice that were immunized by i.v. injection with 1 x 10^5 dendritic cells transduced with different constructs before inoculated intradermally inoculated EL4-MAGE-3 tumor cells. Figure 16A shows the tumor volumes. Figure 16B shows the percentage of surviving mice in each group.
Figure 17 illustrates the charged amino acid residues of HPV 16E7, which were deleted to stabilize the protein and facilitate secretion.

Figure 18 illustrates a schematic representation of expression vectors. The HBe-Fc fusion gene, HBcAg (cytosolic) gene, HBeAg (secretory) gene, or Fc cDNA fragment with a signal sequence (secretory) was cloned into the pRc/CMV vector under the CMV promoter control, respectively. The black square represents the signal sequence.

Figure 19A and Figure 19B show the expression of HBe-Fc, HBcAg, HBeAg, and Fc constructs. Figure 19A shows the expression of the different constructs expressed in cells as determined by Western blot analysis. Figure 19B shows the protein band intensity of the Western blot in Figure 19A analyzed by a PhosphoImager (Molecular Dynamics) with an Image-Quant software.

Figure 20 illustrates the in vivo induction of T-cell responses of mice after DNA immunization with different plasmids or primed T cells that were sacrificed 4 weeks after immunization. Splenocytes were re-stimulated by HBe/cAg recombinant proteins for 5 days.

Figure 21A, Figure 21B, Figure 21C and Figure 21D illustrate the in vivo induction of CD4+ T-cell responses of mice that were immunized with different plasmids and sacrificed 4 weeks after immunization. Figure 21A and Figure 21B show CD4+ T cells that were co-cultured in duplicate with HBe/cAg pulsed-dendritic cells. Figure 21C and Figure 21D show CD4+ T cells from the HBeFc immunized mice that were co-cultured with HBe/cAg pulsed-dendritic cells in the presence or absence of anti-CD4+ or anti-CD8+ antibodies. The concentrations of IFN-γ and IL-2 in the media were determined by ELISA after 72 hours of co-culture.

Figure 22 illustrates the in vivo induction of CTL responses in splenocytes that were isolated from DNA immunized mice and restimulated in vitro with irradiated EL4-HBcAg cells for 5 days. The restimulated splenocytes (E) were co-cultured for 4 hr with the ³H-labeled target cells, EL4-HbcAg or EL4-MAGE3 (control) (T).

Figure 23 shows the induction of antibody responses. The HBc/eAg-specific Egg antibodies from mice at 4-6 weeks after DNA immunization were determined by ELISA.

Figure 24 illustrates data from the dendritic cell transfer experiment. The CD11c+ dendritic cells were isolated from the splenocytes of donor mice immunized with DNA vaccines. The primed-dendritic cells were injected into the lateral tail vein of syngeneic naive recipients. Two to four weeks after the adoptive transfer, T-cell proliferation assays were performed.

Figure 25 illustrates a schematic of retroviral vectors for the construction of cDNA libraries to identify MHC-II restricted epitopes.

Figure 26 illustrates a schematic of the process to identify MHC-II restricted epitopes capable of eliciting a CD4+ helper T-cell response.

DETAILED DESCRIPTION

[0076] It is readily apparent to one skilled in the art that various embodiments and modifications may be made to the invention disclosed in this Application without departing from the scope of the invention as defined in the claims.

[0077] The term "antibody" as used herein, refers to an immunoglobulin molecule, which is able to specifically bind to a specific epitope on an antigen. Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be immunoactive portions of intact immunoglobulins. Antibodies are typically tetramers of immunoglobulin molecules. The antibodies in the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)₂, as well as single chain antibodies and humanized antibodies (Harlow et al., 1988; Houston et al., 1988; Bird et al., 1988).

[0078] The term "antigen" as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. An antigen can be derived from organisms, subunits of proteins/antigens, killed or inactivated whole cells or lysates. Exemplary organisms include but are not limited to, Helicobacters, Campylobacters, Clostridia, Corynebacterium diphtheriae, Bordetella pertussis, influenza virus, parainfluenza viruses, respiratory syncytial virus, Borrelia burgdorferi, Plasmodium, herpes simplex viruses, human immunodeficiency virus, papillomavirus, Vibrio cholera, E. coli, measles virus, rotavirus, shigella, Salmonella typhi, Neisseria gonorrhoea. Therefore, a skilled artisan realizes that any macromolecule,
including virtually all proteins or peptides, can serve as antigens. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan realizes that any DNA, which contains nucleotide sequences or partial nucleotide sequences of a pathogenic genome or a gene or a fragment of a gene for a protein that elicits an immune response results in synthesis of an antigen. Furthermore, one skilled in the art realizes that the present invention is not limited to the use of the entire nucleic acid sequence of a gene or genome. It is readily inherent that the present invention includes, but is not limited to, the use of partial nucleic acid sequences of more than one gene or genome and that these nucleic acid sequences are arranged in various combinations to elicit the desired immune response.

[0079] The term "autoimmune disease" as used herein is defined as a disorder that results from autoimmune responses. Autoimmunity is an inappropriate and excessive response to self-antigens. Examples include but are not limited to, Addison's disease, Graves' disease, Type I- Diabetes mellitus, Multiple sclerosis, Myxedema, Pernicious anemia, Rheumatic fever, Rheumatoid arthritis, Systemic lupus erythematosus, and ulcerative colitis.

[0080] The term "cancer" as used herein is defined a proliferation of cells whose unique trait-loss of normal controls-results in unregulated growth, lack of differentiation, local tissue invasion, and metastasis. Examples include but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer and lung cancer.

[0081] The terms "cell," "cell line," and "cell culture" as used herein may be used interchangeably. All of these terms also include their progeny, which are any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations.

[0082] The term "cell binding element" as used herein is defined as a portion of a protein, which is capable of binding to a receptor on a cell membrane.

[0083] The term "DNA" as used herein is defined as deoxyribonucleic acid.

[0084] The term "dendritic cell" or "DCs" as used herein is defined as an example of an antigen presenting cell derived from bone marrow.

[0085] The term "epitope" as used herein is defined as small chemical groups on the antigen molecule that can elicit and react with an antibody. An antigen can have one or more epitopes. Most antigens have many epitopes; i.e., they are multivalent. In general, an epitope is roughly 5 amino acids or sugars in size. One skilled in the art understands that generally the overall three-dimensional structure, rather than the specific linear sequence of the molecule, is the main criterion of antigenic specificity.

[0086] The term "expression" as used herein is defined as the transcription and/or translation of a particular nucleotide sequence driven by its promoter.

[0087] The term "expression vector" as used herein refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of control sequences, which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operatively linked coding sequence in a particular host organism. In addition to control sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described infra.

[0088] The term "helper T-cell" as used herein is defined as effector T-cells whose primary function is to promote the activation and functions of other B and T lymphocytes and of macrophages. Most are CD4 T-cells.

[0089] The term "heterologous" as used herein is defined as DNA or RNA sequences or proteins that are derived from the different species.

[0090] The term "homologous" as used herein is defined as DNA or RNA sequences or proteins that are derived from the same species.

[0091] The term "host cell" as used herein is defined as cells that are expressing a heterologous nucleic acid sequences.

[0092] The term "immunoglobulin" or "Ig", as used herein is defined as a class of proteins, which functions as antibodies. The five members included in this class of proteins are IgA, IgG, IgM, IgD, and IgE. IgA functions as the primary antibody that is present in body secretions, such as saliva, tears, breast milk, gastrointestinal secretions and mucus secretions of the respiratory and genitourinary tracts. IgG functions as the most common circulating antibody. IgM is the main immunoglobulin produced in the primary response. It is the most efficient immunoglobulin in agglutination, complement fixation, and other antibody responses, and is important in defense against bacteria and viruses. IgD is the immunoglobulin that has no known antibody function, but may serve as an antigen receptor. IgE is the immunoglobulin that mediates immediate hypersensitivity by causing release of mediators from mast cells and basophils upon exposure to allergens.

[0093] The term "major histocompatibility complex", or "MHC", as used herein is defined as a specific cluster of genes, many of which encode evolutionarily related cell surface proteins involved in antigen presentation, which are among the most important determinants of histocompatibility. Class I MHC, or MHC-I, function mainly in antigen presentation to CD8 T lymphocytes. Class II MHC, or MHC-II, function mainly in antigen presentation to CD4 T lymphocytes.

[0094] The term "polynucleotide" as used herein is defined as a chain of nucleotides. Furthermore, nucleic acids are polymers of nucleotides. Thus, nucleic acids and polynucleotides as used herein are interchangeable. One skilled in the
art has the general knowledge that nucleic acids are polynucleotides, which can be hydrolyzed into the monomeric "nucleotides." The monomeric nucleotides can be hydrolyzed into nucleosides. As used herein polynucleotides include, but are not limited to, all nucleic acid sequences which are obtained by any means available in the art, including, without limitation, recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCR™, and the like, and by synthetic means. Furthermore, one skilled in the art is cognizant that polynucleotides include with limitation mutations of the polynucleotides, including but not limited to, mutation of the nucleotides, or nucleosides by methods well known in the art.

[0095] The term "polypeptide" as used herein is defined as a chain of amino acid residues, usually having a defined sequence. As used herein the term polypeptide is mutually inclusive of the terms "peptides" and "proteins".

[0096] The term "promoter" as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.

[0097] The term "retrogen" or "retrogen fusion protein" as used herein, means a polypeptide having an epitope that is capable of eliciting an immune response in a mammal when expressed and processed as described herein, wherein the polypeptide is fused to a cell binding element.

[0098] The term "retrogen expression vector" as used herein refers to the expression vector comprising at least a polypeptide sequence encoding a signal sequence, an antigen and a cell binding element.

[0099] The term "RNA" as used herein is defined as ribonucleic acid.

[0100] The term "recombinant DNA" as used herein is defined as DNA produced by joining pieces of DNA from different sources.

[0101] The term "recombinant polypeptide" as used herein is defined as a hybrid protein produced by using recombinant DNA methods.

[0102] The term "T-cell" as used herein is defined as a thymus-derived cell that participates in a variety of cell-mediated immune reactions.

[0103] The term "transfected" or "transformed" or "transduced" as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A transformed cell includes the primary subject cell and its progeny.

[0104] The phrase "under transcriptional control" or "operatively linked" as used herein means that the promoter is in the correct location and orientation in relation to the polynucleotides to control RNA polymerase initiation and expression of the polynucleotides.

[0105] The term "vaccine" as used herein is defined as material used to provoke an immune response after administration of the materials to a mammal and thus conferring immunity.

[0106] The term "virus" as used herein is defined as a particle consisting of nucleic acid (RNA or DNA) enclosed in a protein coat, with or without an outer lipid envelope, which is only capable of replicating within a whole cell and spreading from cell to cell.

[0107] One embodiment of the present invention is an expression vector comprising a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked as defined above.

[0108] In specific embodiments, the nucleic acid sequence encoding a fusion protein (antigen-cell binding element) is under transcriptional control of a promoter as defined above. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins.

[0109] At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mamalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 genes, a discrete element overlying the start site itself helps to fix the place of initiation.

[0110] Additional promoter elements, i.e., enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements is frequently flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

[0111] A promoter may be one naturally associated with a gene or polynucleotide sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon. Such a promoter can be referred to as "endogenous." Similarly, an enhancer may be one naturally associated with a polynucleotide sequence, located either downstream or upstream of that sequence. Alternatively, certain advantages will be gained by positioning
In specific embodiments of the present invention, the expression vector comprises a polynucleotide sequence that contains different elements of different transcriptional regulatory regions, and/or mutations that alter expression. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR™, in connection with the compositions disclosed herein (U.S. Patent 4,683,202, U.S. Patent 5,928,906). Furthermore, it is contemplated that direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.

A specific embodiment of the present invention is an expression vector wherein the polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a B cell response in a mammal into which said antigen is introduced. Another embodiment of the present invention is an expression vector wherein the polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a CD8+ T-cell response and a CD8+ T-cell response in a mammal into which said antigen is introduced.

A specific embodiment of the present invention is an expression vector wherein the polynucleotide sequence encoding an antigen comprises a polynucleotide sequence for a plurality of epitopes, wherein said plurality of epitopes induces a B cell response, a CD4+ T-cell response and a CD8+ T-cell response in a mammal into which said antigen is introduced.
encoding an antigen as defined above.

[0121] In specific embodiments of the present invention, the expression vector, further comprises a polynucleotide sequence encoding a cell binding element as defined above. The cell binding element is a portion of a polypeptide, which facilitates binding of a protein to a cell receptor.

[0122] In addition to using portions of known binding elements, a skilled artisan is cognizant that small peptides could be identified via a typical screening procedure well known in the art. A DNA library (cDNA or genomic) is screened to identify small peptides that bind efficiently to antigen presenting cells.

[0123] In expression, one will typically include a polyadenylation sequence to effect proper polyadenylation of the transcript. The nature of the polyadenylation sequence is not believed to be crucial to the successful practice of the invention, and/or any such sequence may be employed. Preferred embodiments include the SV40 polyadenylation sequence, LTR polyadenylation sequence, and/or the bovine growth hormone polyadenylation sequence, convenient and/or known to function well in various target cells. Also contemplated as an element of the expression vector is a transcriptional termination site. These elements can serve to enhance message levels and/or to minimize read through from the inserted polynucleotide sequences encoding the antigen and cell binding elements into other sequences of the vector.

[0124] A specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.

[0125] In order to propagate a vector in a host cell, it may contain one or more origins of replication sites (often termed "ori"), which is a specific nucleic acid sequence at which replication is initiated. Alternatively an autonomously replicating sequence (ARS) can be employed if the host cell is yeast. In instances wherein it is beneficial that the expression vector replicate in a cell, the vector may integrate into the genome of the cell by way of integration sequences, i.e., retrovirus long terminal repeat sequences (LTRs), the adeno-associated virus ITR sequences, which are present in the vector, or alternatively, the vector may itself comprise an origin of DNA replication and other sequence which facilitate replication of the vector in the cell while the vector maintains an episomal form. For example, the expression vector may optionally comprise an Epstein-Barr virus (EBV) origin of DNA replication and sequences which encode the EBV EBNA-1 protein in order that episomal replication of the vector is facilitated in a cell into which the vector is introduced. For example, DNA constructs having the EBV origin and the nuclear antigen EBNA-1 coding are capable of replication to high copy number in mammalian cells and are commercially available from, for example, Invitrogen (San Diego, CA).

[0126] It is important to note that in the present invention it is not necessary for the expression vector to be integrated into the genome of the host cell for proper protein expression. Rather, the expression vector may also be present in a desired cell in the form of an episomal molecule. For example, there are certain cell types in which it is not necessary that the expression vector replicate in order to express the desired protein. These cells are those which do not normally replicate, such as muscle cells, and yet are fully capable of gene expression. An expression vector may be introduced into non-dividing cells and express the protein encoded thereby in the absence of replication of the expression vector.

[0127] To identify cells that contain the nucleic acid constructs of the present invention, the cells are identified in vitro or in vivo by including a marker in the expression vector. Such markers confer an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive selectable marker is one, in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

[0128] Usually the inclusion of a drug selection marker aids in the cloning and identification of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers including screenable markers such as GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized. One of skill in the art would also know how to employ immunologic markers in conjunction with FACS analysis. For example, NGFR (nerve growth factor receptor) is included in the expression vector to facilitate selection of cells comprising the vector by using a flow cytometric assay detecting NGFR expression on the cell surface. The marker used is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product. Further examples of selectable and screenable markers are well known to one of skill in the art.

[0129] The expression vector may also comprise a prokaryotic origin of DNA replication and a gene encoding a detectable marker for selection of prokaryotic cells comprising the expression vector, for example, an antibiotic resistance
gene, such as, for example, the ampicillin resistance gene.

In addition, the expression vector may be provided to the cell in the form of RNA instead of DNA. The core components of the vector are the same as those described herein for a DNA vector, and in addition, other components may be added which serve to stabilize the RNA in bodily fluids and in tissues and cells.

The actual methods of ligating together the various components described herein to generate the expression vector of the invention are well known in the art and are described, for example, in Sambrook et al. (1989), Ausubel et al. (1994), and in Gerhardt et al. (1994).

In specific embodiments, the expression vector is selected from the group consisting of viral vectors, bacterial vectors and mammalian vectors. Numerous expression vector systems exist that comprise at least a part or all of the compositions discussed above. Prokaryotic and/or eukaryotic-vector based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patent No. 5,871,986, 4,879,236 and can be bought, for example, under the name MAXBAC® 2.0 from IN VITROGEN® and BACPACK™ BACULOVIRUS EXPRESSION SYSTEM FROM CLON-TECH®.

Other examples of expression vector systems include STRATAGENE®'s COMPLETE CONTROL™ Inducible Mammalian Expression System, which involves a synthetic eddysone-inducible receptor, or its pET Expression System, an E. coli expression system. Another example of an inducible expression system is available from IN VITROGEN®, which carries the T-REX™ (tetracycline-regulated expression) System, an inducible mammalian expression system that uses the full-length CMV promoter. IN VITROGEN® also provides a yeast expression system called the Pichia methanolica Expression System, which is designed for high-level production of recombinant proteins in the methylotrophic yeast Pichia methanolica. One of skill in the art would know how to express a vector, such as an expression construct, to produce a nucleic acid sequence or its cognate polypeptide, protein, or peptide.

A transformed cell comprising an expression vector is generated by introducing into the cell the expression vector of the present invention. The introduction of DNA into a cell or host cell is well known technology in the field of molecular biology and is described, for example, in Sambrook et al. (1989), Ausubel et al. (1994), and in Gerhardt et al. (1994). Methods of transfection of cells include calcium phosphate precipitation, liposome mediated transfection, DEAE dextran mediated transfection, electroporation and the like. Alternatively, cells may be simply transduced with the retrogen expression vector of the invention using ordinary technology described in the references and examples provided herein. The host cell includes a prokaryotic or eukaryotic vector, and it includes any transformable organism that is capable of replicating a vector and/or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors. Host cells may be derived from prokaryotes or eukaryotes, depending upon whether the desired result is replication of the vector or expression of part or all of the vector-encoded nucleic acid sequences.

Numerous cell lines and cultures are available for use as a host cell, and they can be obtained through the American Type Culture Collection (ATCC), which is an organization that serves as an archive for living cultures and genetic materials (www.atcc.org). It is well within the knowledge and skill of a skilled artisan to determine an appropriate host. Generally this is based on the vector backbone and the desired result. A plasmid or cosmid, for example, can be introduced into a prokaryotic host cell for replication of many vectors. Bacterial cells used as host cells for vector replication and/or expression include DH5α, JM109, and KC8, as well as a number of commercially available bacterial hosts such as SURE® Competent Cells and SOLOPACK™ Gold Cells (STRATAGENE®, La Jolla, CA). Alternatively, bacterial cells such as E. coli LE392 could be used as host cells for phage viruses. Eukaryotic cells that can be used as host cells include, but are not limited to yeast, insects and mammals. Examples of mammalian eukaryotic host cells for replication and/or expression of a vector include, but are not limited to, HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Examples of yeast strains include, but are not limited to, YPH499, YPH500 and YPH501. Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector may be used in conjunction with either an eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector.

Further, the expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (1989), and in Ausubel et al. (1994), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses.

Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would further understand the conditions under which to incubate all of the described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.

A specific embodiment of the present invention is a fusion protein comprising a signal sequence and an antigen...
and a cell binding element as defined above. The invention also includes the use of the retrogen protein or fusion protein as a vaccine as defined above. The retrogen protein may be obtained during the expression of the retrogen protein in any cell comprising the expression vector and separating the retrogen protein from the cell, cell debris and cell medium. Affinity column purification procedures may be especially useful for purification of the retrogen of the invention because the retrogen, by definition comprises a cell binding element. An affinity column comprising the matching cellular receptor, or a generic protein such as protein A or protein G, may be used to separate the retrogen from the cellular components. Another embodiment is a vaccine comprising antigen presenting cells that are transduced in vitro with the fusion protein. 

In further embodiments, a vaccine comprises the expression vector, wherein said expression vector comprises a polynucleotide sequence encoding a promoter sequence, a polynucleotide sequence encoding a secretion signal sequence, a polynucleotide encoding an antigen, a polynucleotide encoding a cell binding element, and a polynucleotide encoding a polyadenylation sequence, all operatively linked as is defined above. The vaccine comprising the expression vector is to be administered directly to the mammal to sites in which there are cells into which the sequences contained within the vector may be introduced, expressed and an immune response against the desired protein may be elicited. In this instance, the expression vector is to be administered in a pharmaceutical carrier and in a formulation such that the DNA is capable of entering cells, and being expressed therein. The expressed protein may then enter antigen presenting cells for processing and MHC presentation as described herein. A skilled artisan realizes that the DNA may be given in a variety of ways and, depending upon the route of injection, the composition of DNA may need to be manipulated. Exemplary routes of parenteral injections include, but are not limited to, intramuscular, intraperitoneal, intravenous, subcutaneous and intradermal. Further, it is not necessary that the DNA of the expression vector be introduced into the cells of the mammal by direct injection of the same into the tissues of the mammal. Rather, other means of introduction of the expression vector into the mammal may be used, including, but not limited to non-invasive pressure injection, nasal, oral, etc.

The amount of DNA which is to be introduced into the mammal is an amount sufficient for efficient expression of the DNA in the cell, such that a sufficient amount of protein is expressed and secreted therefrom, which protein is then taken up by antigen presenting cells and expressed thereon as an MHC complex. Such an amount of DNA is referred to herein as a “therapeutic amount” of DNA. The precise concentration of DNA which constitutes a therapeutic amount may be easily determined by one skilled in the art of administration of such compounds to mammals, and will of course vary depending on the components contained therein, and other factors including, but not limited to, the tissue into which the DNA is being introduced and the age and health of the mammal.

Another specific embodiment of the present invention is a vaccine comprising cells that are transduced with the expression vector as defined above. These transduced cells are in the form of a pharmaceutical composition for administration to a mammal for the purpose of eliciting an immune response therein. Expression of the retrogen protein in the cells results in secretion of the retrogen protein from the cells. Secreted retrogen protein may then be taken up by antigen presenting cells in the mammal for processing therein and expression therefrom as a MHC-I or a MHC-II complex. When the eukaryotic cell is an antigen presenting cell, the retrogen protein may be expressed therein, secreted therefrom and may reenter the cell for processing and antigenic MHC presentation. When the eukaryotic cell is not an antigen presenting cell, the cell expresses and secretes the retrogen protein, which is subsequently taken up by an antigen presenting cell for antigenic MHC presentation. Non-antigen presenting cells useful in the invention include any cell which does not process antigens for MHC presentation, i.e., muscle cells. Antigen presenting cells include dendritic cells (DC), macrophages, monocytes and the like. Tumor cells, which are also included, may be cells, which are or are not capable of processing antigens for MHC presentation.

The expression vector may also be introduced into stem cells of a mammal which are not human embryonic stem cells, either directly in vivo in the mammal, or more preferably, ex vivo in cells which are removed from the mammal and are reintroduced into the mammal following introduction of the vector into the cells. The expression vector may also be introduced into other cells in the mammal in an ex vivo approach. When the vector is introduced into cells in the mammal, it is not necessary that the vector express the protein encoded thereby immediately, in that, it may be more desirable that the protein be expressed in the cells at some later time. In this instance, the expression vector preferably comprises an inducible promoter, which is activated upon administration of the appropriate inducer to the mammal or to cells of the mammal. Ex vivo technology is well known in the art and is described, for example, in U.S. Patent No. 5,399,346.

A further embodiment is an expression vector comprising at least a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen and a polynucleotide encoding a cell binding domain as defined above.

Another embodiment of the present invention is the use of the expression vector of the present invention for preparing a medicament to elicit an immune response, as defined above, in particular to manipulate cells to produce endogenous antigens as if they were exogenous antigens. This novel antigen presentation strategy involves transducing cells with a novel recombinant expression vector to produce and secrete a fusion protein consisting of an antigen and a cell-binding element. The secreted fusion protein is endocytosed or “retrogradely” transported into antigen presenting cells via receptor-mediated endocytosis (Daeron, 1997; Serre et al., 1998; Ravetch et al., 1993). As a result, the fusion
protein, or "retrogren" as termed in the present disclosure because of its retrograde transport following secretion, is
processed in the endosomal pathway and is presented on the cell surface of the antigen presenting cells as an MHC-II
restricted exogenous antigenic fragments even though it has been produced endogenously. The MHC-II bound antigenic
fragments of the antigen on the surface of the antigen presenting cells activate CD4+ T-cells that in turn stimulate CD8+
T-cells and macrophages, as well as B-cells to induce both cellular and humoral immunity.

[0145] It has also been discovered in the present invention that the retrogen protein may also be processed in the
cytosolic pathway during the fusion protein synthesis, secretion and endocytosis and become associated with MHC-1
on the surface of the antigen presenting cells to directly activate CD8+ T-cells. Activation of CD8+ T cells by internalized
antigens is described in the art and for example, in Kovacsovics-Bankowski et al., 1995. In addition, as noted above
and described in more detail elsewhere herein, B cells may be activated by the secreted retrogen. Thus, B cell activation
is enhanced markedly in the present system in that CD4+ cells also activates B cells. Thus, this strategy uses a unifying
mechanism to activate all of the arms of the immune system.

[0146] In specific embodiments, the expression vector for introduction into a cell is for producing a transduced cell.
Expression of the retrogen protein in the cells results in secretion of the retrogen protein from the cells. Secreted retrogen
protein may then be taken up by antigen presenting cells in the mammal for processing therein and expression therefrom
as a MHC-I or a MHC-II complex. Thus, one skilled in the art realizes that the transduced cell or first cell, secretes the
antigen and the secreted antigen is internalized into a cell, a second cell, either the same cell or a different cell. When
the eukaryotic cell is an antigen presenting cell, the retrogen protein may be expressed therein, secreted therefrom and
may reenter the cell for processing and antigenic MHC presentation. When the eukaryotic cell is not an antigen presenting
cell, the cell expresses and secretes the retrogen protein, which is subsequently taken up by an antigen presenting cell
for antigenic MHC presentation. Non-antigen presenting cells useful in the invention include any cell which does not
process antigens for MHC presentation, i.e., muscle cells. Antigen presenting cells include dendritic cells (DC), macro-
phages, monocytes and the like. Tumor cells, which are also included, may be cells, which are or are not capable of
processing antigens for MHC presentation.

[0147] A further embodiment of the present invention, is the use of the expression vector for preparing a medicament
in order to elicit an immune response directed against an antigen by direct administration of the medicament to a mammal.

[0148] The invention also includes a method of screening or identifying a polynucleotide sequence which encodes at
least one MHC-II restricted epitope that is capable of eliciting an immune response in a mammal as is defined above.
Preferably, the polypeptide, which is identified, is one which elicits an immune response that is beneficial to the mammal.
The method comprises obtaining a population of isolated DNA molecules and screening for those isolated DNA molecules
which encode at least one MHC-II restricted epitope that is capable of activating CD4+ helper T-cells. The DNA molecules
are referred to herein as "test DNA" or "test polynucleotide sequence." The test polynucleotide sequences are cloned
into the expression vector of the present invention, in the vector which is positioned between the signal sequence and
the cellular binding element as depicted, for example, in Figure 25. In the method, antigen presenting cells are transduced
by introducing the vector comprising the test polynucleotide sequence into the antigen presenting cells, transduced
antigen presenting cells are contacted with naive T-cells or primed T-cells and the ability of the transduced cells to
activate naive CD4+ T cells in vitro is assessed by assessing whether any naive T-cells or primed T-cells are activated
upon contact with said transduced antigen presenting cell. Activation of T cells by transduced antigen presenting cells
is an indication that the test polynucleotide sequence contained therein is a polynucleotide sequence, or gene or fragment
which encodes at least one epitope capable of activating CD4+ helper T-cells to elicit an immune response to a mammal.
Suitable controls which can be used in the assay include cells which are transduced with an expression vector
comprising an isolated polynucleotide sequence which is known not to activate the immune response in a mammal
(negative control), and cells which are transduced with an expression vector comprising an isolated polynucleotide
sequence which is known to activate the immune response in a mammal (positive control). One skilled in the art is
cognizant that this screening procedure can be utilized to screen the human genome to identify genes that encode
proteins or epitopes that are recognized by CD4+ T-cells that could be used for immunotherapy for cancer or autoimmune
disease or for gene therapy. Furthermore, other genomes can be screened including bacterial, viral, or parasitic.

[0149] The in vitro T-cell activation assay may be adapted to be a high-throughput automated assay in order to facilitate
the testing of many different test polynucleotide sequences at one time. One skilled in the art recognizes that the present
invention can be manipulated to transduce cells with expression vectors containing a variety of possible epitope se-
quences. The transduced cells may be placed in 96-well plates, containing naive T-cells, and the activation of the T-
cells may be assessed by automated assessment of incorporation of radioactivity into the DNA of the T-cells, using
technology readily available in clinical immunology.

[0150] In further embodiments, the protein product encoded by the test polynucleotide sequences may be further
evaluated to assess activation of the immune response in a mammal in vivo. This assay is the same as the in vitro assay
except, the transduced antigen presenting cells that were transduced by introducing the expression vector comprising
the test polynucleotide sequences are administered to a mammal via a parenteral route. In specific embodiments, the
expression vector comprising the test polynucleotide sequences is administered directly to a mammal. T-cells are col-
extracted from splenocytes and co-cultured with dendritic cells. The activation of T-cells is assessed to determine if the test polynucleotide encoding the test polypeptide is a capable of activating CD4+ helper T cells. Furthermore, one skilled in the art is cognizant that this screening procedure could be utilized to identify MHC-II restricted epitopes that could be used to treat cancer, viral infections and autoimmune disease.

[0151] As noted herein, the test polynucleotide sequences may be obtained by any ordinary means common in the art of molecular biology. For example, test polynucleotide sequences may be obtained from an expression library, which library may express proteins whose function is unknown. Test polynucleotide sequences may also be obtained from an expression library which expresses proteins of known function, but which have not heretofore been known to possess the property of activation of the immune system in an mammal. Exemplary expression cDNA libraries include, but are not limited to, tumor cells, viral genomes, bacterial genomes, parasitic genomes, and human genomes. Test polynucleotide sequences may also be obtained using combinatorial methodology, wherein it is not known at the outset whether the polynucleotide sequence encodes a protein, and moreover, it is not known whether the polynucleotide sequence encodes a protein which is capable of activating the immune response. Test polynucleotide sequences may also be obtained by synthetic methods, wherein a polynucleotide sequence is synthesized in an automated synthesizer, fragments of discrete lengths are cloned into the expression vector and are tested as described herein.

[0152] It is not always necessary that the immune response be protective, but merely that it be beneficial to the host mammal. For example, it may be beneficial to a mammal to induce immune tolerance in situations wherein an immune response to an antigen is detrimental to the mammal, for example, in certain autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, multiple sclerosis, Crohn’s disease, etc., a diminution in the immune response is desired which can be achieved by inducing immune tolerance against the offensive antigen. In this instance, the DNA comprises DNA encoding the offensive antigen which is then expressed in cells of the mammal and subsequently processed in antigen presenting cells so as to be expressed on the surface thereof as an MHC-I and/or an MHC-II complex in order to induce immune tolerance in the mammal against the antigen.

[0153] In a further embodiment, an identified polynucleotide sequence is useful in a method of treating cancer, viral infection or an autoimmune disease. More particularly, the identified polynucleotide encoding a test polypeptide is transduced into antigen presenting cells and the transduced antigen presenting cells are administered directly to a mammal via a parenteral route to treat cancer, a viral infection or an autoimmune disease. Furthermore, the expression vector containing at least the polynucleotide encoding a test polypeptide and a cell binding element is administered directly into a mammal via a parenteral route to treat cancer, a viral infection or an autoimmune disease.

[0154] A further embodiment of the present invention is a method of producing a vaccine as defined above to immunize a mammal comprising the steps of: transducing antigen presenting cell by introducing the expression vector of the present invention into a cell and expressing said vector to produce an antigen under conditions wherein said antigen is secreted from the cell. In specific embodiments, antigen presenting cells are transduced with the antigen in vitro or ex vivo prior to administering the antigen presenting cells to the mammal. All of the vaccines of the present invention can be administered parenterally.

[0155] In specific embodiments, the approach of inducing an immune response as of the uses as defined above comprises the step of co-administering to an organism the expression vector and a cytokine expression vector. A number of studies have shown that the responses to individual plasmids can be enhanced by co-administration of a cytokine expressing plasmid. It should be noted that picogram to nanogram quantities of locally synthesized cytokine from the expression vector are too low to have systemic effects on the whole mammal, but can still strongly influence the local cytokine environment and thus the immune response to the administered antigen. Examples of cytokines include, but are not limited to, GM-CSF and IL-2. A skilled artisan readily recognizes that the polynucleotide sequences for a cytokine and the polynucleotide sequences for the antigen can be incorporated into one expression vector; thus eliminating the use of two separate vectors. In addition to cytokines, plasmids that contain unmethylated CpG sequences enhance the cell mediated (Th1) response (Carson et al., 1997). CpG sequence motifs include but are not limited to, RRCpGYY. Thus, a skilled artisan realizes that supplementation of a cytokine with the expression vector or addition of a CpG sequence motif in the present invention would result in the enhancement of the immune response.

[0156] In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements are able to bypass the ribosome scanning scanning of 5’ methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988). IRES elements from two members of the picornavirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian message (Macejak and Sarnow,1991). IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together; each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple nucleic acid sequences can be efficiently expressed using a single promoter/enhancer to transcribe a single message (U.S. Patent 5,925,565 and 5,935,819). Furthermore, a skilled artisan is cognizant that the entire nucleic acid sequence of a gene does not have to be used. Instead, partial nucleic acid sequences of MHC class I and II restricted epitopes can be fused together, resulting in a chimeric fusion gene transcribed by one
promoter. For example, a specific embodiment of the present invention is a method of simultaneously inducing both
CD4+ and CD8+ T-cells comprising the steps of administering a fusion protein wherein the protein comprises both a
MHC-I and MHC-II epitope fused to a cell binding element. Thus, one skilled in the art recognizes that the use of multiple
antigenic sequences results in the treatment of a variety of diseases with the administration of one vaccine.

[0157] Another specific embodiment of the present invention is an approach of inducing an immune response as of
the uses as defined above comprising the steps of administering to a mammal one expression vector, wherein said
expression vector comprises a polynucleotide sequence encoding a first fusion protein and a polynucleotide sequence
encoding a second fusion protein under transcriptional control of one promoter, wherein said first fusion protein comprises
a first signal sequence, a first antigen and a first cell binding element and said second fusion protein comprises a second
signal sequence, a second antigen and a first cell binding element. In specific embodiments, the first and second signal
sequences are the same signal sequence, the first and second antigens are different antigens and the cell binding
elements is a Fc fragment. In further embodiments, the first and second signal sequences are the same, the first and
second antigens are different antigens and the first and second cell binding elements are the same cell binding elements.
Further embodiments include, the first and second signal sequences are different, the first and second antigens are
different antigens and the first and second cell binding elements are the same cell binding elements or the first and
second signal sequences are the same, the first and second antigens are different antigens and the first and second
cell binding elements are different cell binding elements. An additional embodiment includes that the polynucleotide
sequence encoding the first fusion protein and the polynucleotide sequence encoding the second fusion protein are
under separate transcriptional control, and wherein the polynucleotide sequence encoding the first fusion protein and
the polynucleotide sequence encoding the second fusion protein are in tandem in one expression vector.

[0158] One skilled in the art is cognizant that multiple nucleic acid sequences can be cloned into the vector in tandem
such that each nucleic acid sequence is a separate entity. Each entity contains a promoter that drives the expression
of the individual nucleic acid sequence resulting in expression of separate antigens from one vector. This technique
efficiently expresses nucleic acid sequences using multiple promoters to transcribe the individual messages.

[0159] A further embodiment of the present invention is a method of producing a fusion protein as defined above
comprising the steps of introducing the expression vector of the present invention into a cell and expressing said vector
to produce a fusion protein under conditions wherein said fusion protein is secreted from the cell. In specific embodiments,
antigen presenting cells are transduced with the fusion protein in vitro. More particularly, the fusion protein is administered
parenterally to a mammal.

[0160] A specific embodiment of the present invention is a method of secreting an intracellular protein as defined
above comprising the steps of introducing an expression vector into a cell, wherein said expression vector comprises a
polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an intra-
cellular protein, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence, all
operatively linked and expressing said vector to produce a fusion protein under conditions wherein said fusion protein
is secreted from the cell. More specifically, the polynucleotide sequence encoding the intracellular protein is truncated
or mutated to increase efficiency of secretion. In specific embodiments, the intracellular protein is HPV 16 E7.

[0161] Another specific embodiments of the present invention is a method of secreting a membrane protein as defined
above comprising the steps of introducing an expression vector into a cell, wherein said expression vector comprises a
polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding a membrane
protein, a polynucleotide encoding a cell binding elements, and a polynucleotide polyadenylation sequence, all operatively
linked and expressing said vector to produce a fusion protein under conditions wherein said fusion protein is secreted
from the cell. More specifically, the polynucleotide sequence encoding the membrane protein is truncated or mutated
to increase efficiency of secretion. In specific embodiments, the membrane protein is EBV nuclear antigen 1.

[0162] The invention also includes a kit comprising the composition of the invention and an instructional material that
describes adventitiously administering the composition to a cell or a tissue of a mammal. In another embodiment, this kit
comprises a (preferably sterile) solvent suitable for dissolving or suspending the composition of the invention prior to
administering the compound to the mammal.

Dosage and Formulation

[0163] The expression vectors, transduced cells and fusion proteins (active ingredients) of this invention can be
formulated and administered to treat a variety of disease states by any means that produces contact of the active
ingredient with the agent's site of action in the body of the organism. They can be administered by any conventional
means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a
combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a
pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

[0164] The active ingredient can be administered orally in solid dosage forms such as capsules, tablets and powders,
or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions. The active ingredient can also be formulated
for administration parenterally by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption. The agent may be administered intramuscularly, intravenously, or as a suppository.

[0165] Gelatin capsules contain the active ingredient and powdered carriers such as lactose, sucrose, Mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

[0166] Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

[0167] In general, liquid oral solutions contain, for example, water, diluents such as sugar or alcohol, and flavoring. The liquid can also contain an antiseptic preservative, such as bensyl alcohol, benzyl benzoate, and the like.

[0168] The active ingredients of the invention may be formulated to be suspended in a pharmaceutically acceptable dosage form suitable for use in mammals and in particular, in humans. Such formulations include the use of adjuvants such as muramyl dipeptide derivatives (MDP) or analogs that are described in U.S. Patent Nos. 4,082,735; 4,082,736; 4,101,536; 4,185,089; 4,235,771; and 4,406,890. Other adjuvants, which are useful, include alum (Pierce Chemical Co.), lipid A, trehalose dimycolate and dimethyl dioctadecylammonium bromide (DDA), Freund's adjuvant, and IL-12. Other components may include a polyoxypolyethylene-polyoxyethylene block polymer (Pluronic®), a non-ionic surfactant, and a metabolizable oil such as squalene (U.S. Patent No. 4,606,918).

[0169] Additionally, standard pharmaceutical methods can be employed to control the duration of action. These are well known in the art and include control release preparations and can include appropriate macromolecules, for example polymers, polyesters, polyanamic acids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate. The concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release. Additionally, the agent can be incorporated into particles of polymeric materials such as polymers, polyanamic acids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.

[0170] Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.

[0171] Capsules: Capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligram of powdered active ingredient, 175 milligrams of lactose, 24 milligrams of talc and 6 milligrams magnesium stearate.

[0172] Soft Gelatin Capsules: A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are then washed and dried.

[0173] Tablets: Tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient. 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of cornstarch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or to delay absorption.

[0174] Injectable: A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

[0175] Suspension: An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution U.S.P. and 0.025 milliliters of vanillin.

[0176] Accordingly, the pharmaceutical composition of the present invention may be delivered via various routes and to various sites in an mammal body to achieve a particular effect (see, e.g., Rosenfeld et al., 1991; Rosenfeld et al., 1991a; Jaffe et al., supra; Berkner, supra). One skilled in the art will recognize that although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, peritoneal, subcutaneous, intradermal, as well as topical administration.

[0177] The active ingredients of the present invention can be provided in unit dosage form wherein each dosage unit, e.g., a teaspoonful, tablet, solution, or suppository, contains a predetermined amount of the composition, alone or in appropriate combination with other active agents. The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for human and mammal subjects, each unit containing a predetermined quantity of the compositions of the present invention, alone or in combination with other active agents, calculated in an amount sufficient
to produce the desired effect, in association with a pharmaceutically acceptable diluent, carrier, or vehicle, where appropriate. The specifications for the unit dosage forms of the present invention depend on the particular effect to be achieved and the particular pharmacodynamics associated with the pharmaceutical composition in the particular host.

These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan. Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

**Lipid Formulation and/or Nanocapsules**

In certain embodiments, the use of lipid formulations and/or nanocapsules is contemplated for the introduction of the expression vector, into host cells.

Nanocapsules can generally entrap compounds in a stable and/or reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkylcyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention, and/or such particles may be easily made.

In a specific embodiment of the invention, the expression vector may be associated with a lipid. The expression vector associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lip, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. The lipid or lipid/expression vector associated compositions of the present invention are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with a “collapsed” structure. They may also simply be interspersed in a solution, possibly forming aggregates which are not uniform in either size or shape.

Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which are well known to those of skill in the art which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

Phospholipids may be used for preparing the liposomes according to the present invention and may carry a net positive, negative, or neutral charge. Diacetyl phosphate can be employed to confer a negative charge on the liposomes, and stearylamine can be used to confer a positive charge on the liposomes. The liposomes can be made of one or more phospholipids.

A neutrally charged lipid can comprise a lipid with no charge, a substantially uncharged lipid, or a lipid mixture with equal number of positive and negative charges. Suitable phospholipids include phosphatidyl cholines and others that are well known to those of skill in the art.

Lipids suitable for use according to the present invention can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine (“DMPC”) can be obtained from Sigma Chemical Co., dicetyl phosphate (“DCP”) is obtained from K & K Laboratories (Plainview, NY); cholesterol (“Chol”) is obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, AL.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20°C. Preferably, chloroform is used as the only solvent since it is more readily evaporated than methanol.

Phospholipids from natural sources, such as egg or soybean phosphatidylcholine, brain phosphatidic acid, brain or plant phosphatidylinositol, heart cardiolin and plant or bacterial phosphatidylethanolamine are preferably not used as the primary phosphatide, i.e., constituting 50% or more of the total phosphatide composition, because of the instability and leakiness of the resulting liposomes.

“Liposome” is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes may be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). However, the present invention also encompasses compositions that have different structures in solution than the normal vesicular structure. For example, the lipids may assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes.

Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios the liposome is the preferred structure. The physical characteristics of liposomes depend on pH, ionic strength and/or the presence of divalent cations. Liposomes can show low permeability to ionic and/or polar substances, but at elevated temperatures undergo a phase transition which markedly alters their
Liposomes interact with cells via four different mechanisms: Endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and/or neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic and/or electrostatic forces, and/or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and/or by transfer of liposomal lipids to cellular and/or subcellular membranes, and/or *vice versa*, without any association of the liposome contents. Varying the liposome formulation can alter which mechanism is operative, although more than one may operate at the same time.


Dried lipids or lyophilized liposomes prepared as described above may be dehydrated and reconstituted in an aqueous solution of inhibitory peptide and diluted to an appropriate concentration with a suitable solvent, e.g., DPBS. The amount of nucleic acid encapsulated in the liposome preparation, the liposomal pellets washed. The washed liposomes are resuspended at an appropriate total phospholipid concentration,

Dried lipids can be hydrated at approximately 25-50 mM phospholipid in sterile, pyrogen-free water by shaking until all the lipid film is resuspended. The aqueous liposomes can then be separated into aliquots, each placed in a vial, lyophilized and sealed under vacuum.

In the alternative, liposomes can be prepared in accordance with other known laboratory procedures: the method of Bangham et al. (1965), the contents of which are incorporated herein by reference; the method of Gregoriadis, as described in DRUG CARRIERS IN BIOLOGY AND MEDICINE, G. Gregoriadis ed. (1979) pp. 287-341, the contents of which are incorporated herein by reference; the method of Deamer and Uster, 1983, the contents of which are incorporated by reference; and the reverse-phase evaporation method as described by Szoka and Papahadjopoulos, 1978. The aforementioned methods differ in their respective abilities to entrap aqueous material and their respective aqueous space-to-lipid ratios.

The dried lipids or lyophilized liposomes prepared as described above may be dehydrated and reconstituted in a solution of inhibitory peptide and diluted to an appropriate concentration with an appropriate solubilizing agent, e.g., DPBS. The mixture is then vigorously shaken in a vortex mixer. Unencapsulated nucleic acid is removed by centrifugation at 29,000 x g and the liposomal pellets washed. The washed liposomes are resuspended at an appropriate total phospholipid concentration, e.g., about 50-200 mM. The amount of nucleic acid encapsulated can be determined in accordance with standard methods. After determination of the amount of nucleic acid encapsulated in the liposome preparation, the liposomes may be diluted to appropriate concentrations and stored at 4°C until use.

A pharmaceutical composition comprising the liposomes will usually include a sterile, pharmaceutically acceptable carrier or diluent, such as water or saline solution.
Gene Therapy Administration

[0198] One skilled in the art recognizes that the expression vector-of the present invention can be utilized for gene therapy. For gene therapy, a skilled artisan would be cognizant that the vector to be utilized must contain the gene of interest operatively linked to a promoter. For antisense gene therapy, the antisense sequence of the gene of interest would be operatively linked to a promoter. One skilled in the art recognizes that in certain instances other sequences such as a 3’ UTR regulatory sequences are useful in expressing the gene of interest. Where appropriate, the gene therapy vectors can be formulated into preparations in solid, semisolid, liquid or gaseous forms in the ways known in the art for their respective route of administration. Means known in the art can be utilized to prevent release and absorption of the composition until it reaches the target organ or to ensure timed-release of the composition. A pharmaceutically acceptable form should be employed which does not ineflectuate the compositions of the present invention. In pharmaceutical dosage forms, the compositions can be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. A sufficient amount of vector containing the therapeutic nucleic acid sequence must be administered to provide a pharmacologically effective dose of the gene products.

[0199] One skilled in the art recognizes that different methods of delivery may be utilized to administer a vector into a cell. Examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure); and (2) methods wherein said vector is complexed to another entity, such as a liposome, aggregated protein or transporter molecule.

[0200] Accordingly, the present invention provides a method of transferring a therapeutic gene to a host, which comprises administering the vector of the present invention, preferably as part of a composition, using any of the aforementioned routes of administration or alternative routes known to those skilled in the art and appropriate for a particular application. Effective gene transfer of a vector to a host cell in accordance with the present invention to a host cell can be monitored in terms of a therapeutic effect (e.g. alleviation of some symptom associated with the particular disease being treated) or, further, by evidence of the transferred gene or expression of the gene within the host (e.g., using the polymerase chain reaction in conjunction with sequencing, Northern or Southern hybridizations, or transcription assays to detect the nucleic acid in host cells, or using immunoblot analysis, antibody-mediated detection, mRNA or protein half-life studies, or particularized assays to detect protein or polypeptide, encoded by the transferred nucleic acid, or impacted in level or function due to such transfer).

[0201] These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan. Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

[0202] Furthermore, the actual dose and schedule can vary depending on whether the compositions are administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. Similarly, amounts can vary in in vitro applications depending on the particular cell line utilized (e.g., based on the number of vector receptors present on the cell surface, or the ability of the particular vector employed for gene transfer to replicate in that cell line). Furthermore, the amount of vector to be added per cell will likely vary with the length and stability of the therapeutic gene inserted in the vector, as well as also the nature of the sequence, and is particularly a parameter which needs to be determined empirically, and can be altered due to factors not inherent to the methods of the present invention (for instance, the cost associated with synthesis). One skilled in the art can easily make any necessary adjustments in accordance with the exigencies of the particular situation.

[0203] It is possible that cells containing the therapeutic gene may also contain a suicide gene (i.e., a gene which encodes a product that can be used to destroy the cell, such as herpes simplex virus thymidine kinase). In many gene therapy situations, it is desirable to be able to express a gene for therapeutic purposes in a host cell but also to have the capacity to destroy the host cell once the therapy is completed, becomes uncontrollable, or does not lead to a predictable or desirable result. Thus, expression of the therapeutic gene in a host cell can be driven by a promoter although the product of said suicide gene remains harmless in the absence of a prodrug. Once the therapy is complete or no longer desired or needed, administration of a prodrug causes the suicide gene product to become lethal to the cell. Examples of suicide gene/prodrug combinations which may be used are Herpes Simplex Virus-thymidine kinase (HSV-tk) and ganciclovir, acyclovir or FIAU; oxidoreductase and cycloheximide; cytosine deaminase and 5-fluorocytosine; thymidine kinase thymidilate kinase (Tdk::Tmk) and AZT; and deoxycytidine kinase and cytosine arabinoside.

[0204] The following examples are offered by way of example, and are not intended to limit the scope of the invention as defined in the claims.

Example 1

Construction and Expression of HBe Antigen in a Retroviral Vector

[0205] Although both HBCAg and HBeAg proteins are encoded by the HBVpre-CC gene, the secretory HBeAg protein
To assess the "retrogen" strategy in DCs, the retroviral vectors containing the HBeAg gene, with murine stem cell factor (SCF) and IL-6, were produced from PA317 packaging cells using the transient transfection method. The truncated HBeAg gene was then fused in-frame with an IgG Fc fragment. The HBe-retrogen fusion gene (HBe-retrogen) was cloned into the retroviral vector (LNC-NGFR), or the expression vector pHCMV. The vectors comprising HBcAg (cytosolic) and HBeAg (secretory) were constructed using technology available in the art and described, for example in, Sambrook et al. (1989) and in Ausubel et al. (1997). The IgG Fc fragment gene was fused with an IgG signal leader sequence and was cloned into the expression vectors as shown in Figure 2A. In this manner, a series of control retroviral vectors containing the HBeAg gene (secretory), the Fc fragment gene with a signal leader sequence (secretory), or the HBcAg gene (cytosolic), were constructed as represented in Figure 2A.

**Example 2**

**Transduction and Expression of HBe-Retrogen in Dentritic Cells (DCs)**

To assess the expression and secretion of the HBe-Fc fusion protein, COS cells were transfected with various expression vectors and 48 hours later, the cells were radiolabeled. As shown in Figure 3, a protein band corresponding to the HBeAg-Fc fusion protein, was detected in both cell lysates and culture medium when either was precipitated with an anti-human IgG or anti-HBeAg antibody (Sigma Chemical Co. St. Louis, MO).

**Evaluation of Transduction (Measurement of Expression)**

After several days in culture, the cells exhibited typical DC morphology and high levels of MHC, adhesion, and co-stimulation molecules (CD11, CD54, CD80 and CD86) were expressed on the bone-marrow-derived DCs (Figures 4A-4C and 5A-5E). About 20 to 30% of the cells in the culture were transduced, as determined by anti-NGFR staining. Transcription of the HBe-retrogen gene in the DCs was demonstrated in a RT-PCR assay.
the cDNAs were used as templates for a PCR reaction using a pair of primers corresponding to the HBeAg gene. The PCR products were analyzed by electrophoresis through agarose.

**Example 3**

**In vitro Activation of Naive CD4+ T-cells**

[0214] To evaluate whether the transduced DCs were capable of priming naive CD4+ T-cells in cell culture, naive CD4+ T-cells isolated from C57BL/6 mouse spleen cells were co-cultured with murine DCs transduced with the retroviral vectors of Example 1 at a ratio of 1:20 (DCs:T-Cells). CD4+ T cells were isolated from the suspension of mouse spleens using a CD4+ T cell enriching column (R&D Systems, Minneapolis, MN). CD8+ T cells were isolated from the suspension of mouse spleens using a CD8+ T cell enriching column (R&D System, Minneapolis, MN). Purified CD4+ or CD8+ T cells were cultured in RPMI-1640 supplemented with 10% FBS at 37°C and 5% CO2.

[0215] When naive CD4+ T-cells were co-cultured with the DCs transduced with either HBcAg, HBeAg or Fc fragment gene, only low or background levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)-γ were detected by ELISA in the culture medium. Further, no apparent T-cell proliferation was observed when either cell numbers or the incorporation rate of 3H-thymidine was monitored. In contrast, when naive CD4+ T-cells were co-cultured with the DCs transduced with the HBe-retrogen for 5 days, T-Cells actively proliferated and high levels of GM-CSF and IFN-γ were detected in the culture medium (Figures 6A and 6B). These results suggest that secretory HBeAg or cytosolic HBcAg could not be efficiently processed and presented to MHC-II by DCs. In contrast, secretory HBe-retrogens could be efficiently processed following Fc-receptor-mediated internalization and presentation to MHC-II in DCs, leading to the in vitro activation of naive CD4+ T-cells.

[0216] No apparent naive CD8+ T-cell activation was detected in the co-culture with the transduced DCs. The failure to detect naive CD8+ T-cell activation in the cell-culture may be due to the fact that there is only one known MHC-I restricted epitope in the HBeAg and that CD4+ T-cells are required for efficient activation of CD8+ T-cells (Ridge et al., 1998).

[0217] To further demonstrate MHC-II-restricted antigen presentation using the retrogen strategy, MHC-II knockout (KO) C57BL/6 mice, in which MHC-II antigen presentation by DCs was abolished, were used (Charles River, NY). DCs derived from wild-type (WT) or MHC-II KO mice were transduced with the HBe-retrogen and were then co-cultured with CD4+ T-cells obtained from WT mice at a ratio of 1:20. As shown in Figures 6A and 7B, only low levels of GM-CSF and IFN-γ were detected in the culture medium containing the transduced KO-DCs, and no apparent T-cell proliferation was observed. In contrast, when CD4+ T-cells were co-cultured with the transduced WT DCs for 5 days, the T-cells actively proliferated and high levels of GM-CSF and IFN-γ in the culture medium were detected (Figures 6A and 6B).

**Example 4**

**In vivo Induction of Helper and Cytotoxic T-cell, and B-cell Immune Response**

[0218] The potential of the retrogen antigen presentation strategy was evaluated in vivo. Mice (C57BL/B6) were divided into four groups (4 to 6 mice/group) and each mouse was administered about a half a million of the DCs that were transduced with HBeAg, HBcAg, Fc, or HBe-retrogen in 0.2 ml PBS containing 50,000 U IL-2 (Chiron Corp. Emeryville, CA) by intraperitoneal injection. At the different times post-final administration, the mice were sacrificed and peripheral blood, spleen and other organs were collected. T-cells were isolated for analysis using the CD4 or CD8+ T-cell enriching columns (R&D System, Minneapolis, MN).

[0219] Three months after the first injection, mice were sacrificed and the peripheral blood, spleen, and other tissue samples were collected. From gross pathology, the lymph nodes in the peritoneal cavity were significantly enlarged in the mice administered the HBe-retrogen-transduced DCs, while in normal mice and mice administered other constructs, the lymph nodes were too small to be visible. Histologic examination also revealed active proliferation of T-cells and B-cells in the peritoneal lymph nodes of mice administered the HBe-retrogen-DCs.
Example 5

Induction of T_H1 and T_H2 Helper T-Cells

Mice immunized as in Example 4 were used to determine the induction of T_H1 and T_H2 helper T-cells. Skilled artisans are cognizant of the importance of determining the induction of T_H1 and T_H2 cells. It is well known that CD4+-T-cells perform the following functions: 1) they help B-cells develop into antibody producing plasma cells; 2) they help CD8+-T-cells to become activated cytotoxic T-cells; and 3) they effect delayed hypersensitivity. These functions are performed by two subpopulations of CD4 cells: T_H1 cells mediate delayed hypersensitivity and produce primarily IL-2 and gamma interferon (IFN-γ), whereas T_H2 cells perform the B-cell helper function and primarily produce IL-4 and IL-5.

CD4+-T-cells were isolated from the spleens of the immunized mice using an anti-CD4 column (R&D Systems, Minneapolis, MN) and these cells were then co-cultured with DCs of mice that were pulsed with a recombinant HBeAg protein. After only 2 days in co-culture of cells having a ratio of T-cells:DCs of 1000:1, the CD4+-T-cells from mice administered the HBe-retrogen-DCs actively proliferated. High levels of GM-CSF and IFN-γ (stimulate macrophages and CD8+-T-cells), as well as IL-4 and IL5 (stimulate B-cells), were detected in the culture medium. Anti-CD4 antibodies, but not anti-CD8 antibodies, dramatically blocked cytokine production in these co-cultured T-cells. In contrast, when the CD4+-T-cells obtained from mice immunized with HBeAg-, HBcAg-, or Fc-DCs were co-cultured with HBeAg-DCs, only low levels of GM-CSF, IFN-γ, IL-4, and IL-5 were detected in the co-culture medium, and no active T-cell proliferation was observed. Since IL-4 and IL-5 are mainly produced by T_H2 and GM-CSF and IFN-γ by T_H1 cells, the results demonstrate that HBe-retrogen-transduced DCs effectively activate both T_H1 and T_H2 T-cells.

Examples 6

Induction of High Titers of Anti-HBeAg Antibodies

Mice were immunized as in Example 4 to determine the level of antibodies. Immunization of mice with HBe-retrogen-transduced DCs induced high-titer, long-lasting anti-HBe/cAg antibody responses in mice. As shown in Figure 8, significantly higher titers of anti-HBeAg antibodies were detected in the sera of the mice administered the HBe-retrogen-transduced DCs than in the mice administered HBeAg-transduced DCs. The levels of anti-HBeAg antibodies in the sera of immunized mice were assessed using an ELISA. Briefly, microtiter plates coated with HBcAg recombinant proteins (50 ng/well) were incubated with serially diluted sera in a blocking buffer at 4°C for 2 hours. Bound antibody was detected after incubation with peroxidase-conjugated antibodies to mouse IgG diluted in blocking buffer. A polyclonal anti-HBcAg antibody obtained from Chiron Corp. (Emeryville, CA) was used as positive control, and normal mouse sera was used as a negative control. The antibody titer was defined as the highest dilution having an OD_{450} value, which was two times above the negative level.

The fold increase of the antibody production observed may be due to the stronger activation of CD4+ helper T-cells. The significantly lower levels of anti-HBe/cAg antibodies in the sera of the mice immunized with HBcAg-transduced DCs may be due to the cytosolic location of HBcAg and lack of CD4+ T-cell activation. Thus, the HBe-retrogen is significantly superior to other HBeAg and HBcAg constructs for the induction of an antibody response in mammals immunized with the same. Taken together, the results of the mouse model study demonstrate that DCs transduced with HBe-retrogen induced vigorous CD4+ and CD8+-T-cell activation, as well as, B-cell activation.

Example 7

Vector Construction of an Intracellular Tumor Antigen

MAGE-3 is a cytosolic and nuclear protein lacking a targeting sequence for the endogenous MHC-II presentation pathway, which makes its presentation on MHC-II unlikely or difficult. Since there is no mouse homolog, a human MAGE-3 gene was linked to a signal leader sequence derived from a human chemokine RANTES gene to allow the secretion of MAGE-3. A plasmid encoding the full-length MAGE-3 gene was used as a template to amplify the MAGE-3 DNA with a pair of primers: 5’-primer (A): (SEQ. ID. No. 1) 5’-ACGCCGTGACATGCCTCTTTGAGCAGAGGAGTCAG-3’, corresponding to the polynucleotide sequence 1 to 24 of the MAGE-3 gene with an additional Sal I restriction site, and 3’-primer (B): (SEQ. ID. No. 2) 5’-CCGTCGAGTACTTCCCTCTCTCA.A.AAC-3’, corresponding to the polynucleotide sequence 921 to 945 of the MAGE-3 with a Xho I site. The addition of the signal leader sequence derived from the human RANTES gene was generated by PCR amplification with a pair of primers: 5’-primer (C): (SEQ. ID. No. 3) 5’-ACCGGTCCGATGAAGGTCTCCCGGCGGACGCCTCGGTG CATCCTATTGTCATCGCCTCGTGTCGT GCATTCTGATGCCTCTTTGAGCAGAGGAGTCA-3’, corresponding to the RANTES signal leader sequence and to the polynucleotide sequence 1 to 24 of the MAGE-3 gene with a Sal I site, and 3’-Primer-B. The signal-MAGE-3 fragment
After extensive washing with RPMI-1640, the cells were incubated with rabbit complement (Calbiotech) and a cocktail of monoclonal antibodies consisting of anti-CD4, anti-CD8, anti-CD45R/B220, and anti-MHC-II (PharMingen and BioSource International) in RPMI-1640 at 37°C for 40-60 min. After extensive washing with RPMI-1640, cells (5x10^5 cells/ml) in RPMI-1640 supplemented with 6% FBS, 80 ng mSCF/ml (R&D Systems), and 20 Units (U) mIL-4/ml (BioSource International) were plated in 12-well culture plates (2.5 ml/well), incubated at 37°C, 5% CO_2 overnight, and then refed with fresh medium. After 48-hour incubation, the cells were spun down, resuspended in 1.5 ml of the retrovirus supernatants, placed onto 24-well culture plates coated with Retronectin (PanVera) at a concentration of 10-20 ng/ml, and incubated at 37°C, 5% CO_2 for 3-4 hour. The supernatants were then replaced with 1.5 ml of RPMI-1640 supplemented with 5% FBS, 10 ng murine stem cell factor (mSCF)/ml, 60 ng mGM-CSF/ml (BioSource International) and 100 U mIL-4/ml (R & D Systems) overnight. The transduction procedure was repeated 2-3 times and about 30% of BM cells were usually transduced by this procedure. After the final transduction, the cells were washed and cultured in Opti-MEM (Gibco-BRL) containing mGM-CSF and mIL-4 for several days to allow further DC differentiation. DCs were further enriched with a 50% FCS-RPMI-1640 sedimentation procedure, as described previously (Inaba et al., 1992). After several days of culture, a substantial fraction of the cells showed distinct DC morphology. The s-MAGE-3-Fc, s-MAGE-3, MAGE-3, or Fc gene in the transduced DCs was transcribed, as demonstrated by reverse transcription (RT)-PCR assays. Quantitative Western blotting analysis was used to demonstrate protein expression and secretion by the constructs in transduced DCs. Briefly, the transduced DCs were lysed with a buffer (Boehringer Mannheim) (10 mM Tris 150 mM NaCl (pH 7.4), 1%TX-100 (Sigma), 0.5 mM PMSF, and protease inhibitor cocktail tablets) on ice for 10
min. Cell lysates and culture media were then precipitated with a rabbit polyclonal antibody against MAGE-3, followed by incubation with Protein A-Sepharose (Sigma). The precipitates were then resuspended in 20 μl loading buffer. The protein samples (20 μl) were loaded onto a 10% SDS-PAGE gel and transferred to a Hybond PVDF membrane (Amer sham Pharmacia Biotech), which was blocked by overnight incubation in PBS (pH7.5) containing 5% non-fat dried milk (Carnation) and 0.1% (v/v) Tween-20 (Fisher Scientific) at 4°C. After washing with a buffer (PBS containing 0.1% (v/v) Tween-20), the membrane was incubated with a mouse monoclonal antibody against MAGE-3 diluted in a PBS buffer containing 2.5% non-fat milk and 0.1% Tween-20 (1:400) at room temperature for 1 hour. After washing, the membrane was then incubated with a horseradish peroxidase (HRP) labeled anti-mouse IgG (Amer sham Pharmacia Biotech) in a buffer (1: 10,000) at room temperature for 1 hour. After a final wash, the membrane was visualized with an ECL-Plus chemiluminescent detection kit (Amersham Pharmacia Biotech) and exposed on a Kodak film. Protein band intensity of the Western blot on the film was determined and analyzed by a PhosphorImager (Molecular Dynamics) with an ImageQuant software 1.2 version. It was found that the s-MAGE-3-Fc and s-MAGE-3 proteins were efficiently produced and secreted from DCs, while MAGE-3 was retained intracellularly (Figures 9B and 9C). Comparable levels of s-MAGE-3-Fc, s-MAGE-3, and MAGE-3 proteins were expressed in the transduced DCs.

Example 9

Interaction of Fc on DC

[0227] Interaction of Fc with FcγRs on DCs triggers cell activation, causing the up-regulation of cell surface molecules involved in antigen presentation. Surface markers were examined to evaluate whether the expression of s-MAGE3-Fc in the transduced DCs could induce DC activation. Surface markers of DCs transduced with s-MAGE-3-Fc, s-MAGE-3, or vector, were measured by flow cytometric assays. Briefly, the DCs were pre-incubated with an anti-CD16/CD32 antibody (2.4G2, PharMingen) for blocking FcγRs at 4°C for 30-60 min. The DCs were then incubated with primary antibodies at 4°C for 30 min, followed by incubation with an anti-mouse or -rabbit IgG-FITC conjugate. After extensive washing, the DCs were analyzed by a FACScan (Becton Dickinson) with CellQuest software. As shown in Figures 9D, 9E and 9F, higher levels of MHC class-II, CD40, and CD86 were expressed on DCs derived from BM cells transduced with s-MAGE-3-Fc and on DCs in the presence of LPS than on DCs transduced with s-MAGE-3 or vector control. These results suggest that the secretion and subsequent interaction of the fusion protein Fc with FcγRs activate DCs.

Example 10

Induction of Potent Th1 In Vivo

[0228] To evaluate whether the secretion and subsequent internalization of MAGE-3 can enhance the immunogenicity of this antigen in vivo, DCs were transduced with s-MAGE-3-Fc, s-MAGE-3, MAGE-3, or Fc by retroviral vectors, and then administered i.v. once into C57BL/6 mice (0.5-1 x 10⁵ DC in 30 μl PBS containing 50,000 U IL2(chiron) per mouse). Four to six weeks after immunization, the mice were sacrificed and peripheral bloods, spleens, and other tissue samples were collected. Lymph nodes were substantially enlarged in the mice immunized with s-MAGE-3-Fc-DCs, reminiscent of pathogen infection, but not in the mice administered with DCs transduced with s-MAGE-3, MAGE-3, or Fc.

[0229] To determine if immunization with transduced DCs can induce CD4+ helper T cell responses, CD4+ T-cells from splenocytes of the immunized mice were isolated and then co-cultured with bone-marrow (BM)-derived DCs transduced with s-MAGE-3-Fc. Briefly, CD4+ or CD8+ T-cells were isolated from spleen suspensions with 0.1% DNase I (fraction IX, Sigma) and 1 mg/ml collagenase (Roche Molecular Biochemicals) at 37°C for 40-60 min. DCs were positively isolated from the cell suspensions of lymph nodes or spleens with anti-CD11c (N418) Micro-Beads (Miltenyi Biotec Inc) for further study. During two weeks of co-culture with different ratios of CD4+ T-cells vs DCs, the CD4+ T-cells from mice immunized with s-MAGE-3-DCs, MAGE-3-DCs, or Fc-DCs did not actively proliferate, and only low levels of IL-2, IFN-γ, TNF-α, and IL-4 were detected in the co-culture media (Figures 10A, 10B, 10C and 10D). CD4+ T cells from immunized mice were co-cultured with DCs at a rate of 1000:1 (T cell:DC, 2x10⁵:2x10²) for various times. Supernatants of the co-cultures were harvested and subsequently assayed for cytokine concentrations by ELISA (PharMingen) according to the manufacturer’s instructions (PharMingen). In contrast, in the co-cultures with CD4+ T-cells from mice immunized with s-MAGE-3-Fc-DCs, high levels of IL-2 and IFN-γ were detected in the co-culture media after only 48-hour of co-culture even at a 1:1000 (DC:T-cell) ratio. Anti-CD4, but not anti-CD8 antibodies, blocked the cytokine production by the co-cultured cells (Figure 11 A). Repeated experiments showed similar results. To further determine the specificity of the T-cell responses, BM-derived DCs transduced with a retroviral vector expressing an irrelevant hepatitis B virus core antigen (HBcAg) were co-cultured with CD4+ T cells from s-MAGE-3-Fc-DCs-immunized mice. Only low
levels of IFN-γ, and other cytokines were detected in the co-culture media (Figure 11B). Furthermore, DCs from the lymph nodes of mice six weeks after immunization were isolated with anti-CD11c microbeads (Miltenyi Biotec, Inc.) and co-cultured with CD4+ T cells from the same immunized mice. As shown in Figures 12A, 12B, 12C, and 12D, high levels of IL-2, IFN-γ, and TNF-α were only detected in the co-cultures of the cells from s-MAGE-3-Fc-DCs-immunized mice. These results indicate that the DCs transduced with s-MAGE-3-Fc can home to lymphoid organs or tissues, and activate Th1 responses more efficiently than do DCs transduced with the native MAGE-3 or s-MAGE-3.

Example 11

Induction of CTLs in vivo

[0230] The JAM or "just another method" test was performed to determine whether immunization with s-MAGE-3-Fc-DCs can induce strong CTL responses. The JAM test was used to measure cytotoxic activities. Briefly, mice were sacrificed at different times after immunization and a single-cell suspension of splenocytes was cultured in RPMI 1640 10% FBS. A total of 4x10^6 splenocytes was restimulated with 8x10^5 γ-irradiated (10,000 rad) syngeneic EL4-MAGE-3 cells or EL4-HbcAg cells/2 ml in 24-well plates (Costar) for 4-6 days in 5% CO2 at 37°C, pooled, and then resuspended to 1x10^6 cells/ml. To label the target cells, ^3H-thymidine was added into 5x10^5/ml EL4-MAGE-3 or EL4-HbcAg cells at a final concentration of 2 μCi/ml. After 6 hour incubation, the cells were gently washed once with PBS and resuspended in the culture medium (1x10^6 cells/ml). Different numbers of effector cells were then co-cultured with a constant number of target cells (1x10^6/well) in 96-well round-bottomed plates (200 μl/well) for 4 hour at 37°C, after which the cells and their media were then aspirated onto fiber glass filters (Filter Mate Harvester, Packard) that were then extensively washed with water. After the filters were dried and placed onto 96-well plates, 25 μl MicroScint 20 (Packard) were added to each well. The plates were counted in a TopCount NXT Microplate Scintillation and Luminescence Counter (Packard). In some experiments, the restimulated effector cell populations were incubated with the anti-CD4 or anti-CD8 antibodies (30 μl/well, PharMingen) for 30-60 min to deplete CD4+ or CD8+ T-cells before cytotoxicity assays. The percent of specific killing was defined as: (Target cell DNA retained in the absence of T-cells (spontaneous) - Target cell DNA retained in the presence of T-cells)/spontaneous DNA retained x 100. The value of total ^3H-thymidine incorporation is often similar to the spontaneous retention. Splenocytes from immunized mice were restimulated in vitro in RPMI-1640, 10% FBS with syngeneic cells EL4-MAGE-3, and then co-cultivated with ^3H-thymidine labeled EL4-MAGE-3 cells at various effector/target ratios to measure the specific killing. EL4-MAGE-3 cells were established by transfection with the MAGE-3 expression vector (pcDNA3.1-MAGE-3) and Zeocin (Invitrogen) selection, and shown to express MAGE-3 by PCR and immunoprecipitation assays.

[0231] Splenocytes from mice immunized with s-MAGE-3-Fc-DCs killed target cells much more efficiently than those from mice immunized with s-MAGE-3, MAGE-3, or Fc (Figure 13). The specificity of killing was further demonstrated by the inability of the splenocytes of s-MAGE-3-Fc-DCs-immunized mice to kill EL4-HbcAg cells that express the irrelevant HbcAg (Figure 13), and by the inhibition of killing with the anti-CD8 but not the anti-CD4 antibody. Thus, these results demonstrate the superior ability of s-MAGE-3-Fc-DCs to induce CTL responses, due to the enhanced Th1 and crosspriming of receptor-mediated antigen internalization.

Example 12

Induction of Antibody

[0232] Since antibodies can also play a role in antitumor immunity, anti-MAGE-3 antibody titers in the sera of immunized mice (similar to Example 10) were measured by ELISA. Anti-MAGE-3 antibodies in the sera of immunized mice were detected by ELISA. Briefly, microtiter plates (Dynatech) coated with a recombinant MAGE-3 proteins (50 ng each/well) were incubated with serially diluted sera in a blocking buffer (KPL, Gaithersburg, MD) at room temperature for 2 hour. Bound antibody was detected after incubation with a peroxidase-conjugated antibody against mouse IgG (Sigma) diluted in the blocking buffer. A monoclonal antibody against MAGE-3 was used as a positive control and normal mouse sera as a negative control. The antibody titer was defined as the highest dilution with an OD₄₅₀ greater than 0.2. The background OD₄₅₀ of normal mouse sera was lower than 0.1. Anti-MAGE-3 antibodies were induced 2 weeks after DC immunization and reached the peak 4-6 weeks after immunization.

[0233] As shown in Figure 14, significantly higher titers of anti-MAGE-3 antibodies were detected in the sera of s-MAGE-3-Fc-DC immunized mice than in mice immunized with s-MAGE-3-DGs or MAGE-3-DCs. The specificity of the antibody responses was demonstrated by the lack of antibody against the irrelevant HbcAg in the immunized mice. Taken together, the findings indicate that s-MAGE-3-Fc-DCs are superior to MAGE-3-DCs or s-MAGE-3-DCs in inducing CD4+ Th, CD8+ CTL, as well as B-cell responses.
Example 13

Enhanced Interaction of Helper T-Cells

[0234] Primed CD4+ Tαβ cells that recognize their specific peptides in the context of MHC-II on DCs greatly increase their interaction with conditioned DCs. This interaction via CD40-CD40L can trigger DC production of IL-12 and is critical for generating T-cell helper for CTL responses. To test if this approach can enhance CD4+ Tαβ interaction with s-MAGE-3-Fc-DCs, IL-12 production by transduced DCs in co-culture with primed CD4+ T-cells was measured. Primed CD4+ T-cells were isolated from mice immunized with s-MAGE-3-Fc-DCs and then co-cultured with BM-derived DCs transduced with s-MAGE-3-Fc, s-MAGE-3, MAGE-3, or Fc. As shown in Figure 15, a significant increase in IL-12 production was observed in the CD4+ T-cell co-culture with s-MAGE-3-Fc-DCs, but not in the co-cultures with s-MAGE-3-DCs or MAGE-3-DCs. The IL-12 production by s-MAGE-3-Fc-DCs was inhibited by blocking with CD40L on the primed CD4+ T-cells. The expression of Fc in DCs also non-specifically enhanced IL-12 production to a lesser degree. These results, together with the in vivo results of Examples 10, 11, and 12 data, indicate that the secretion and subsequent FcRs-mediated internalization of MAGE-3 lead to the cross-presentation of MAGE-3 on DCs for the induction of Tαβ1 and CTL responses.

Example 14

Protective Immunity Induced by s-MAGE-3-Fc-DCs

[0235] To examine if the enhanced anti-MAGE-3 immune responses could lead to effective anti-tumor immunity, challenge experiments were performed. The EL4-MAGE-3 cell line was derived from the parental tumor EL-4 line that grows rapidly in syngeneic mice and used for challenge experiments. When intradermally implanted into syngeneic C57BL/6 mice, EL4-MAGE-3 cells (0.5 to 1 x 10^6 cells) showed aggressive tumor growth similar to that of parental EL-4 cells, producing visible tumors in mice by only 3-5 days after inoculation and resulting in mouse death usually within one month after inoculation. To test the ability of s-MAGE-3-Fc-DCs to inhibit EL4-MAGE-3 tumor growth, mice were immunized i.v. twice (7 day interval) with 1x10^5 DCs transduced with s-MAGE-3-Fc, s-MAGE-3, MAGE-3 or Fc, followed by challenge with the EL4-MAGE-3 cells (1 x 10^6). C57BL/6 mice were immunized by i.v. injection with 1x10^5 transduced DCs on day 0 and day 7, and then intradermally challenged with 1x10^6 exponentially growing EL4-MAGE-3 or EL4-HbAg cells 1 week after the second immunization. Tumor sizes were measured every 2 to 3 days, with tumor volumes calculated as follows: (longest diameter x (shortest diameter))^2.

[0236] As shown in Figure 16A, tumor growth was inhibited to a much greater extent in mice immunized with s-MAGE-3-Fc-DCs, although immunization with s-MAGE-3-DCs, MAGE-3-DCs, or even Fc-DCs (a non-specific immune stimulator) did confer some degree of protection. The potency of the antitumor activity shown by these constructs correlated with their abilities to induce immune responses. Consistently, the mice immunized with s-MAGE-3-Fc-DCs survived considerably longer than mice immunized with other vector-transduced DCs (Figure 16B). The antitumor activity induced by the s-MAGE-3-Fc-DCs was specific, since mice immunized with s-MAGE-3-Fc-DCs and challenged with wild type EL4 or EL4-HbAg cells also developed lethal tumors and died within one month. S-MAGE-3-Fc-DCs also partially inhibited the growth of established EL4-MAGE-3 tumors in mice, even though the immune system may not have sufficient response time to effectively control rapidly lethal tumor growth in this model.

Example 15

Construction of an HBe Antigen in a Mammalian Expression Vector

[0237] A plasmid encoding the full-length HBV (adw subtype) genome was obtained from the American Type Culture Collection (ATCC). The HBV precore/core gene was found to contain a single base pair deletion, which causes a frameshift at codon 79, resulting in two consecutive stop codons at 84 and 85. This gene was repaired by inserting the deleted base using PCR mutagenesis and confirmed by DNA sequencing. The full-length HBeAg gene was generated by PCR amplification of the repaired HBV genome with a pair of primers (5'-primer (P-A): (SEQ: ID. No. 9) 5'-TTAAGCTTTAGCAACCTTCTGCCTAATC-3', corresponding to the polynucleotide sequence 1904 to 2020 of the HBV genome with an additional HindIII restriction site, and 3'-primer (P-B): (SEQ: ID. No. 10) 5'-TTCCTGAACTCAGATTAACTTTTGAGCCAAGA-3', corresponding to the polynucleotide sequence 2437 to 2457 of the HBV genome with additional XbaI and C1aI sites). The truncated HBeAg gene with the deletion of the arginine-rich, C'-terminal sequence of HBeAg (aa 150-185) that is cleaved during viral infection, was generated by PCR amplification with a pair of primers (5'-primer: 5'- TTAAAGCTTTAGCAACCTTCTGCCTAATC-3', corresponding to the polynucleotide sequence 1904 to 2020 of the HBV genome with an additional HindIII restriction site, and 3'-primer (P-B): (SEQ: ID. No. 10) 5'-TTCCTGAACTCAGATTAACTTTTGAGCCAAGA-3', corresponding to the polynucleotide sequence 2437 to 2457 of the HBV genome with additional XbaI and C1aI sites). The truncated HBeAg gene was generated by PCR amplification with a pair of primers (5'-primer:
Induction of T H 1, Helper T-Cells by HBe-Fc DNA Vaccine in Vivo

Example 16

Induction of T H 1, Helper T-Cells by HBe-Fc DNA Vaccine in Vivo

[0239] Mice were immunized to evaluate this strategy in vivo. C57BL/6 or BALB/c mice were divided into four groups and each mouse was immunized with one i.m. injection of 100 μg (25-50 μg/μl per quadriiceps) HBeAg, HBeAg, Fc, or HBe-Fc DNA. After 2-4 weeks of immunization, the mice were sacrificed and peripheral blood, spleens, and other tissue samples were collected.

[0240] First, Splenocytes from the mice 2-4 weeks after-immunization with DNA vaccines were re-stimulated with the recombinant HBeAg proteins for 5 days. T-cells were isolated from restimulated splenocytes, and then assessed by using the 3H-thymidine incorporation assay. As shown in Figure 20, T cells from the mice immunized with HBe-Fc DNA construct or with HBe-Fc DNA vaccine primed T cells actively proliferated. In contrast, the T cells from the mice immunized with HBeAg, HBeAg, or Fc DNA vaccine or HBeAg, HBeAg and Fc DNA vaccine primed T cells did not actively proliferate.

[0241] CD4+ T-cells from the immunized mice were co-cultured with DCs that were pulsed with recombinant HBeAg
and HBcAg, similar to Example 5. During 6 days of co-culture with different ratios of T-cells vs DCs, CD4+ T-cells from the mice immunized with HBeAg, HBcAg or Fc construct did not actively proliferate, and only low levels of IL-2 and IFN-γ were detected in the co-culture media (Figure 21A and Figure 21B). In contrast, in the co-cultures with the CD4+ T-cells from the mice immunized with HBe-Fc construct, CD4+ T-cells actively proliferated after only 48-hour co-culture even at a 1:1000 (DC:T-cells) ratio. Further, levels of IL-2 and IFN-γ in the co-culture media were significantly higher than those in the co-cultures with the CD4+ T-cells from the mice administered with HBeAg or HBcAg construct (Figure 21A and Figure 21B). Anti-CD4, but not anti-CD8 antibodies, dramatically blocked the production of these cytokines by the co-cultured cells (Figure 21C and Figure21D). In addition, an irrelevant antigen, the recombinant HBsAg protein (American Research Product, Boston, MA), was used to pulse DCs in parallel with HBe/cAg. The HBsAg-pulsed DCs were unable to stimulate the CD4+ T-cells of HBe-Fc construct immunized mice in the described assay, demonstrating the specificity of CD4+ T helper 1 cell responses induced by HBe-Fc construct immunization. These results indicate that the HBe-Fc construct can more efficiently activate Th1 than can the HBeAg or HBcAg constructs. Significant levels of IL-4 were not detected in any of the experiments. Since IL-2 and IFN-γ are mainly produced by Th1 cells, the results indicate that HBe-Fc construct induces Th1 response.

Example 17

Induction of CTLs in vivo

[0242] To determine whether immunization with HBe-Fc construct can induce CTL responses, a JAM test was performed, similar to Example 11. Splenocytes from different immunized mice were restimulated in vitro for 4-6 days in medium containing synthetic peptide HBcAg13-27 and then co-cultivated with [3H]-labeled, peptide (HBcAg13-27)-pulsed target cells EL-4 (H-2b) and p815 (H-2d) at varied effector/target ratios to measure target cell killing. As shown in Figure 22, splenocytes from mice immunized with HBe-Fc construct demonstrated significantly higher target cell killing than those from mice immunized with HBeAg or HBcAg. The specificity of the killing was demonstrated by the inability of the splenocytes to kill HBcAg-pulsed p815 target cells with an H-2d background, and the inhibition of the killing by the anti-CD8, but not anti-CD4 antibody. Furthermore, HBsAg was also used to restimulate splenocytes from HBe-Fc construct immunized mice, and no significant killing to HBcAg-pulsed target cells was observed by the HBsAg-restimulated splenocytes. The superior cytotoxicity response induced by HBe-Fc construct is due to the enhanced T-helper 1 and the direct-MHC class-1 presentation of internalized HBe-Fc fusion protein by DCs.

Example 18

Induction of Antibody

[0243] To determine whether HBe-Fc-DC immunization can induce antibody responses, anti-HBe/cAg antibody titers were measured in the pooled sera of mice immunized with different vectors, similar to Example 6. As shown in Figure 23, anti-HBe/cAg antibodies were detected in the sera of mice immunization with HBe-Fc construct. The specificity of the antibody responses was demonstrated by the lack of antibody against HBsAg in the immunized mice. By contrast, significantly lower antibody titers were detected in mice immunized with HBeAg or HBcAg construct (Figure 23). Taken together, HBe-Fc DNA is significantly superior to DNAs expressing native HBeAg or HBcAg in inducing CD4+ T helper 1 and CD8+ cytotoxic T-cell, as well as B-cell responses.

Example 19

Systemic Activation of DCs by HBe-Fc DNA Vaccination.

[0244] To evaluate the possibility of the HBe-Fc or HBeAg proteins being secreted from the transduced cells and circulating throughout the body to perform antigen presentation, a DC transfer experiment was performed. DCs were isolated from immunized mice and transferred into naive mice to assess whether the transferred DCs can prime naive CD4+ and CD8+ T-cells. Mice immunized with the HBeAg-Fc, PEA-HBe, or control DNA vaccine were sacrificed one month later. Mouse CD11c (N418) MicroBeads (Miltenyi Biotec) were used to isolate DCs from mouse spleens. CD11c+ DCs were injected (IP or IV) into naive mice (about 1-5 x 10^5/mouse). Two to four weeks after the DC transfer, the mice were sacrificed and the antigen-specific CD4+ and CD8+ T-cell responses of different mice are monitored. As shown in Figure 24, DCs from splenocytes of HBe-Fc immunized mice efficiently activate naive T-cell responses, while DCs from splenocytes of HBe or HBc immunized mice failed to activate T-cell in naive mice. This result, together with results of the PCR and internalization assays, indicate that DC antigen presentation is enhanced by FcγR-mediated antigen endocytosis.
Example 20

Secretion of Altered Membrane and Intracellular Proteins

Membrane proteins and intracellular proteins, which contain a sequence to prevent protein membrane translocation and secretion or lack a signal sequence for secretion, can be used for the strategy of the present invention without further modification. It is envisioned that deletion or mutation of the sequence which blocks a protein from secretion results in protein secretion. Membrane proteins often contain a high proportion of hydrophobic amino acids, thus altering the hydrophobicity of these proteins allows them to be targeted for secretion. One skilled in the art recognizes that the retrogen strategy also can be used to enhance immunogenicity of these proteins. Two examples for the deletion or mutation of membrane proteins are HPV E7 and EBV proteins.

E7 is a cytosolic protein. The presence of a string of charged residues hamper the secretion of the protein. Elimination of these residues facilitate the protein secretion and stabilize the protein (Figure 17). Accordingly, the string of charged residues of HPV 16 E7 proteins was deleted in current construct (solid box) by two PCR reactions. As a result, secretion of the truncated E7 proteins after linking with a leader signal (IL-2) was dramatically enhanced.

EBV nuclear antigen 1 is a nuclear protein, which contains a stretch of hydrophobic amino acid residues which would interfere with protein membrane translocation and secretion. In a study, the stretch of hydrophobic amino acid residues in the EBNA1 protein was deleted. As a result, the truncated EBNA1 protein was efficiently secreted from cells after linking with a leader signal sequence.

In addition to deletion or truncation of the sequence, one skilled in the art recognizes that the sequence can also be mutated to reduce the hydrophobicity of the protein. Site-directed mutagenesis provides for the preparation and testing of sequence variants by introducing one or more polynucleotide sequence changes into a selected DNA.

In general, one first obtains a single-stranded vector, or melts two strands of a double-stranded vector, which includes within its sequence a DNA sequence encoding the desired protein or genetic element. An oligonucleotide primer bearing the desired mutated sequence, synthetically prepared, is then annealed with the single-stranded DNA preparation, taking into account the degree of mismatch when selecting hybridization conditions. The hybridized product is subjected to DNA polymerizing enzymes such as E. coli polymerase I (Klenow fragment) in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed, wherein one strand encodes the original non-mutated sequence, and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate host cells, such as E. coli cells, and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.

Site-directed mutagenesis is disclosed in U.S. Patents 5,220,007; 5,284,760; 5,354,670; 5,366,878; 5,389,514; 5,635,377; and 5,789,166.

In addition to membrane proteins, intracellular proteins are modified, resulting in secretion. One such modification is merely the addition of the signal leader sequence. For example, MAGE is an intracellular protein that lacks a signal sequence for secretion. In Example 7, a signal sequence was added to MAGE by using PCR techniques. The addition of the signal sequence to MAGE enabled this intracellular protein to be secreted. Another modification of an intracellular protein is to alter the precursor, which is typically an intracellular protein, so that it is secreted similar to the mature protein. For example, the IL-1-beta precursor protein is cytosolic, but the mature protein is secreted. Thus, Siders and Mizel (J. Biol. Chem., 1995) truncated amino acid residues in the precursor protein. They illustrated that deletion of a few amino acids between 100 and 104 increased the secretion level of the truncated protein to the level of the mature IL-1 betas. Thus, one skilled in the art would be able to utilize this information to alter other intracellular proteins.

A further modification includes the use of viral particles, which are released from cells. Thus, the retrogen is fused to a viral gene and assembled into viral particles for release. A virus particle consists of a nucleic acid genome surrounded by a shell of protein. Packing of viral particles is performed by any of the methods well-known in the art.

Example 21

Protein Glycosylation

Glycosylation of IgG-Fc is known in the art to be essential for optimal activation of effector cells via FcγR recognition. Thus, recombinant fusion proteins containing the Fc moiety must be generated in a system capable of glycosylation if binding to FcγR is essential for its potential utility. The baculovirus-insect cell system is commonly used to generate high yield recombinant protein. The ability of this system to add a core oligosaccharide and outer arm sugar residues to glycoproteins is well known by the skilled artisan and makes it a suitable system for expression and purification of the HBe-Fc fusion protein.

The 1230 bp HBeFc fragment contained in the tHBeAgFc plasmid, which expresses the secretory HBe-Fc protein consisting of the truncated HBeAg in-frame fused to the IgG Fc, was constructed. Briefly, recombinant HBe-Fc
baculovirus was generated using the pFastBac system (Gibco BRL) with the pFB 1 donor plasmid. The HBe-Fc fragment was first PCR amplified from hHBeAgFc template using the 5’ primer (SEQ. ID. No. 17) -5’-GATGAAATTCT-GCAACTTTTTTCACCTGC-3’ and the 3’ primer (SEQ. ID. NO. 18) 5’-GATCAAAGCTTTCATTTACCCGGAGACAGG-GA-3’ to introduce EcoRI and HindIII restriction sites to the 5’ and 3’ ends, respectively. This PCR product was gel purified, digested, and ligated into EcoRI/HindIII cut pFB donor plasmid. The resultant vector (pFB1-HBeFc) was identified by restriction enzyme analysis and confirmed by DNA sequencing. Site-specific transposition of the HBe-Fc expression cassette from the donor plasmid into the baculovirus genome was performed by transforming DH10Bac E. coli with the pFB1-HBeFc donor plasmid. Recombinant baculoviruses were identified by X-gal selection, as transposition into the bacmid disrupts expression of the lacZα peptide. Recombinant bacmid DNA was isolated by mini-prep and used to transfect Sf9 insect cells according to the manufacturers’ instructions.

[0255] The viral stock obtained from the initial transfection was amplified by infecting a 50 ml suspension culture of Sf9 cells at 2x10^6 cells/ml with 0.5 ml of the viral stock, and collecting the supernatant after 48 hours. This stock was then subjected to two additional rounds of amplification at which point >90% of cells were producing recombinant HBe-Fc as monitored by immunofluorescent staining of infected cells. The amplified stock was then used to infect four 100 ml cultures of Sf9 cells for 72-90 hours. Supernatants were harvested and clarified by centrifugation for 20 minutes at 14,000 RPM, 4°C. The clarified supernatant was then passed twice over a 5ml Detergent Absorber Gel Column (Boehringer Mannheim) to remove pluronic that could interfere with protein recovery. Recombinant HBe-Fc protein was then purified from the supernatant by passage over a protein G column (Pharmacia) at a flow rate of 1 ml/minute. The column was washed sequentially with 10 volumes of 100mM Tris pH 6.0 and 10mM Tris pH 6.0, and the protein eluted in 1 ml fractions with 10 volumes of 100mM Glycine pH 2.7. The pH of all fractions was immediately adjusted to neutral by addition of 1/10 volume 1M Tris pH 8.0. Protein containing fractions were determined by A280 and separated by 12% SDS-PAGE to determine purity. Purified fractions were then subjected to Western Blot. Briefly, 15 µg of the major protein containing eluted fraction was separated by 12% SDS-PAGE under reducing (R) or non-reducing (NR) conditions, transferred to nitrocellulose, blotted, and developed using ECL Western blotting detection reagents. Primary antibody, rabbit anti-HBc; secondary antibody, mouse anti-rabbit-peroxidase conjugate.

Example 22

Identifications of MHC-II-Restricted Antigen

[0256] The present invention is used to identify MHC-II-restricted viral antigens, HIV, HCV, EBV, bacterial antigens, other pathogen antigens, tumor antigens, and self antigens related to autoimmune diseases. The expression vector in the present invention has been modified to include "test" polynucleotides. The polynucleotide sequences that are not known to elicit an immune response. This strategy of the present invention identifies new antigens/epitopes that are used to develop new vaccines.

[0257] First, a cDNA library is constructed using mRNA from selected cells, i.e., tumor cells. When cDNA is prepared from cells or tissue that express the polynucleotide sequences of interest at extremely high levels, the majority of cDNA clones that contain the polynucleotide sequence, which can be selected with minimal effort. For less abundantly transcribed polynucleotide sequences, various methods can be used to enrich for particular mRNAs before making the library. Retroviruses are used as a vector for the library. Retroviral libraries provide the ideal way to deliver a high-complexity library into virtually any mitotically active cell type for expression cloning. Because the viral particles infect the cell, they can be used in any vector. A cDNA library is constructed by using methods well known in the art. Briefly, tumor cell lines are established from tumor samples. CD4+ T-cells from the same mammal peripheral bloods are expanded by co-culture with the mammal tumor lysate-pulsed DCs derived from monocytes/macrophages. These tumor cells that are recognized by expanded autologous CD4+ T-cells are identified. Next, the cell lines are plated in 96 wells. Expanded autologous CD4+ T-cells are added into the 96-wells, and the IFN-γ or GM-CSF concentrations in the 96-well co-cultures are monitored. The next step is to culture and extract mRNA from the positive tumor cells. The isolated mRNA is converted to cDNA and inserted into a vector, for example, lentiviral vector with a GFP marker or the test cDNAs are cloned into the expression vector of the present invention. The test cDNAs are cloned into the vector between the signal sequence and the cellular binding element as depicted, for example, in Figure 25. Once the cDNA library is constructed, the viral vectors are transduced into packaging cells. Next, immature DCs derived from monocytes from the mammal with the same MHC-II genotype are transduced with the recombinant vectors and efficiency is determined. Transduced DCs are co-cultured with expanded autologous CD4+ T-cells. Positive clones are identified by ELISA (GM-CSF) or IL2 surface expression by flow cytometric array. The positive clone is PCR amplified and sequenced to determine the protein (Figure 26).

[0258] The human genome is screened to identify the polynucleotide sequences that encode proteins and epitopes that are recognized by CD4+ T-cells. These polynucleotide products are used for cancer therapy or to induce immune
tolerance for autoimmune disease therapy, or gene therapy. This basic screening procedure provides for the identification of epitopes for designing small therapeutic molecules.

[0259] Thus, a skilled artisan is cognizant that this screening procedure is modified to screen a variety of genomes, i.e., human, viral, bacterial, or parasitic. Construction of cDNA libraries are well known in the art. Thus, a skilled artisan is capable of utilizing this information to alter the present invention to identify antigens.

[0260] All patents and publications mentioned in the specifications are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

REFERENCES CITED


Gerhardt et al. (eds., 1994, Methods for General and Molecular Bacteriology, American Society for Microbiology, Washington, DC).


Rosenfeld et al., Clin. Res., 39(2), 311 A (1991a);

Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York)


van der Bruggen, P. et al., European Journal of Immunology 24, 3038-43 (1994).


Wong et al., Gene, 10:87-94, 1980.


SEQUENCE LISTING

[0262]

<110> CHEN, SI-YI AND ZHAOYANG, YOU

<120> METHODS AND COMPOSITIONS FOR ANTIGENS WHICH ELICIT AN IMMUNE RESPONSE

<130> TBA

<140> TBA

<141> TBA

<150> 60/132,752

<151> 1999-05-06

<150> 60/132,750

<151> 1999-05-06

<160> 19

<170> PatentIn Ver. 2.0

<210> 1

<211> DNA

<212> Homo sapiens

<400> 1

acgcgtcgac atgcctcttg agcagaggag tcag 34

<210> 2

<211> DNA

<212> Homo sapiens

<400> 2

cgcgtcgagt cactcttccc cctctctcaa aac 33

<210> 3

<211> DNA

<212> Homo sapiens

<400> 3

acgcgtcgac atgaaggtct ccgcggcagc cctcgctgtc atcctcattg ctaactgcct 60

cctcgctctgc gcatctgcc a tgcctc tga gcagaggag t cag 103

<210> 4

<211> 38
DNA
Homo sapiens

ataagaatgc ggcgcgtctc ttcccccctct ctcataaac

ataagcggcc gctaaacgct acacatgcc a

ccgctcgtagc cattaccggc gagacagggc gag

gcagctccca gatgggtcct gtccaaaact cacacatgccc accagctc accagctc accagctc accagctc

ttaagcttat gcacattttc cacctggcct taatc

tttctagaat cgattaacat tgagattccc gaga

tagtgcac atgggaacat tgtgtgtctc tcttctctc tgtggcagct cccagatgg 60
tcttgtcc

ttaagcttat gccacttttt cacccttgtc taatc

tttcagaat cgattaacat tgagattccc gaga

Hepatitis B virus

Hepatitis B virus
<211> 37
<212> DNA
<213> Hepatitis B virus

<400> 11
gtgccgccgc tcaacaaca gtagttccg gaagtgt  
37

<210> 12
<211> 40
<212> DNA
<213> Hepatitis B virus

<400> 12
ttaagcttat ggcacattgac cttataaag aatrggagc  
40

<210> 13
<211> 31
<212> DNA
<213> Homo sapiens

<400> 13
ataagcggcc gctaaacact acacatgccc a  
31

<210> 14
<211> 36
<212> DNA
<213> Homo sapiens

<400> 14
tttctagt gatcactca tttacccga gacagg  
36

<210> 15
<211> 55
<212> DNA
<213> Homo sapiens (first 30)/Murine (last 25)

<400> 15
gcagctccca gatggtctct gttcacaact cacacatgcc caccgtgccc agcac  
55

<210> 16
<211> 69
<212> DNA
<213> Murine

<400> 16
ttaagcctca tatggaaca tctgtggttc ttccttcctc tgggtgcacg tccagatgg  
69
gttggtgcc

<210> 17
<211> 31
<212> DNA
<213> Hepatitis B virus

<400> 17
gatcgaattc atgcaacttt ttcctctg  
31
Claims

1. An expression vector comprising a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence; a polynucleotide encoding an infectious disease antigen which is hepatitis B virus E antigen or a cancer antigen, which is MAGE-3, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked, wherein said polynucleotide encoding a cell binding element is a polynucleotide sequence of a ligand which binds to a cell surface receptor and said polynucleotide sequence of a ligand is an Fc fragment.

2. The expression vector of claim 1, wherein said polynucleotide promoter sequence is selected from the group consisting of a constitutive promoter, an inducible promoter and a tissue specific promoter.
3. The expression vector of claim 2, wherein said constitutive promoter is selected from the group consisting of a simian virus 40 (SV40) early promoter, a mouse mammary tumor virus promoter, a human immunodeficiency virus long terminal repeat promoter, a Moloney virus promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, a human actin promoter, a human myosin promoter, a human hemoglobin promoter, cytomegalovirus (CMV) promoter and a human muscle creatine promoter.

4. The expression vector of claim 2, wherein said inducible promoter is selected from the group consisting of a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter.

5. The expression vector of claim 2, wherein said tissue specific promoter is selected from the group consisting of HER-2 promoter and a PSA associated promoter.

6. The expression vector of claim 1, wherein said polynucleotide encoding a signal sequence is selected from the group consisting of a hepatitis B virus E antigen signal sequence, an immunoglobulin heavy chain leader sequence, and a cytokine leader sequence.

7. The expression vector of claim 1, wherein said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a B cell response in a mammal.

8. The expression vector of claim 1, wherein said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a CD4+ T-cell response in a mammal.

9. The expression vector of claim 1, wherein said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a CD8+ T-cell response in a mammal.

10. The expression vector of claim 1, wherein said polynucleotide encoding an antigen comprises a polynucleotide sequence for at least one epitope, wherein said at least one epitope induces a B cell response, a CD4+ T-cell response, and a CD8+ T-cell response in a mammal into which said antigen is introduced.

11. The expression vector of claim 1, wherein said polynucleotide encoding an antigen comprises a polynucleotide sequence for a plurality of epitopes, wherein said plurality of epitopes induces a B cell response, a CD4+ T-cell response, and a CD8+ T-cell response in a mammal into which said antigen is introduced.

12. The expression vector of claim 1, wherein said polynucleotide encoding a cell binding element is a homologous Fc fragment.

13. The expression vector of claim 1, wherein said polynucleotide encoding a cell binding element is a heterologous Fc fragment.

14. The expression vector of claim 1, wherein said expression vector further comprises an integration signal sequence which facilitates integration of said expression vector into the genome of the cell.

15. The expression vector of claim 14, wherein the integration signal sequence is a viral long terminal repeat sequence or an adeno-associated virus ITR sequence.

16. The expression vector of claim 1, wherein the vector is selected from the group consisting of viral vector, bacterial vector and mammalian vector.

17. An isolated transformed cell comprising an expression vector of any of claims 1 to 16, wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence, all operatively linked.

18. The cell of claim 17, wherein said cell is prokaryotic or eukaryotic.

19. The cell of claim 18, wherein said eukaryotic cell is selected from the group of eukaryotic cells consisting of yeast, insect, and mammalian cells.
20. A fusion protein encoded by the expression vector of any of claims 1 to 16.

21. A vaccine comprising an expression vector of any of claims 1-16.

22. A vaccine comprising antigen presenting cells, wherein said antigen presenting cells are transduced in vitro with the fusion protein of claim 20.

23. A vaccine comprising antigen presenting cells, wherein said antigen presenting cells are transduced in vitro with the expression vector of any of claims 1-16.


25. Use of an expression vector of claims 1-16 sequence, for the preparation of a medicament for eliciting an immune response directed against said antigen, wherein said expression vector is for introduction into a cell, and wherein said cell will express said vector to produce said antigen under conditions, wherein said antigen is secreted from the cell; said secreted antigen is endocytosed into the cell; said endocytosed antigen is processed inside the cell; and said processed antigen is presented to a cell surface protein, to elicit a T-cell mediated immune response.

26. The use of Claim 25 wherein the processed antigen is presented to a cell surface protein selected from the group consisting of MHC-I, MHC-II or B-cells receptors.

27. The use of Claim 25 wherein the antigen is secreted by a first cell and internalized by a second cell.

28. The use of Claim 27 wherein the first cell and second cell are antigen presenting cells.

29. The use of Claim 27 wherein the first cell is a non-antigen presenting cell and the second cell is an antigen presenting cell.

30. The use of Claim 29 wherein the first cell is a muscle cell.

31. Use of an expression vector of Claim 1 for the preparation of a medicament for eliciting an immune response directed against an antigen in a mammal, wherein the medicament is for direct administration to said mammal via a parenteral route.

32. A method to identify a polynucleotide sequence which encodes at least one MHC-II restricted epitope that is capable of activating CD4+ helper T cells, said method comprising the steps of:

introducing in vitro an expression vector of any of claims 1 to 16, in which the polynucleotide encoding an antigen is replaced by a polynucleotide that is not known to elicit an immune response, into antigen presenting cells; contacting said transduced antigen presenting cell with naive T-cells or primed T-cells; and assessing whether any naive T-cells or primed T cells are activated upon contact with said transduced antigen presenting cell wherein activation of said T cells indicates that the polynucleotide encoding the test polypeptide is a gene or fragment thereof, which encodes at least one MHC-II restricted epitope that is capable of activating CD4+ helper T cells.

33. The method of Claim 32, wherein the polynucleotide encoding a test polypeptide is a cDNA library isolated from tumor cell lines.

34. The method of Claim 32, wherein the polynucleotide encoding a test polypeptide is selected from the group of cDNA libraries consisting of viral genomes, bacterial genomes, parasitic genomes, and human genomes.

35. A method to identify a polynucleotide sequence which encodes at least one MHC-II restricted epitope that is capable of eliciting an immune response in vivo, said method comprising the steps of:

collecting T-cells from splenocytes in vitro from a mammal to which a transduced antigen presenting cell had been administered via a parenteral route, wherein the transduced antigen presenting cell had been produced by introducing an expression vector of any of claims 1 to 16, in which the polynucleotide encoding an antigen is replaced by a polynucleotide that is not known to elicit an immune response, into antigen presenting cells in vivo.
vitro, and co-culturing said T-cells with dendritic cells; and assessing activation of T-cells wherein said activation of T-cells indicates that the polynucleotide encoding the test polypeptide is a polynucleotide sequence or fragment thereof, which encodes at least one MHC-II restricted epitope that is capable of activating CD4+ helper T cells.

36. A method to identify a polynucleotide sequence which encodes at least one MHC-II restricted epitope that is capable of eliciting an immune response in vivo, said method comprising the steps of:

- collecting T-cells from splenocytes in vitro from a mammal to which an expression vector of any of claims 1 to 16, in which the polynucleotide encoding an antigen is replaced by a polynucleotide that is not known to elicit an immune response, had been administered via a parenteral route and co-culturing said T-cells with dendritic cells; and
- assessing activation of T-cells wherein said activation of T-cells indicate that the polynucleotide encoding the test polypeptide is a polynucleotide sequence or fragment thereof, which encodes at least one MHC-II restricted epitope that is capable of activating CD4+ helper T cells.

37. The method of any of Claims 35 and 36, wherein the polynucleotide encoding a test polypeptide is a cDNA library isolated from tumor cell lines.

38. The method of any of Claims 35 and 36, wherein the polynucleotide encoding a test polypeptide is selected from the group of cDNA libraries consisting of viral genomes, bacterial genomes, parasitic genomes, and human genomes.

39. A method of producing a vaccine to immunize a mammal comprising the steps of:

- transducing antigen presenting cells in vitro by introducing an expression vector of any of claims 1-16 into said antigen presenting cells to produce a transduced antigen presenting cell, all operatively linked; and
- expressing said vector to produce an antigen under conditions wherein said antigen is secreted from the cell.

40. Use of a vaccine of any of Claims 21 to 24 for transducing antigen presenting cells in vitro.

41. Use of a cytokine expression vector and the retrogen expression vector of claim 1 for the preparation of a medicament for inducing an immune response in a mammal.

42. The use of claim 41, wherein the cytokine expression vector contains the sequence for GM-CSF.

43. The use of claim 41, wherein the cytokine expression vector contains the sequence for IL-2.

44. Use of an expression vector for the preparation of a medicament for inducing an immune response in a mammal, wherein said expression vector comprises a polynucleotide sequence encoding a cytokine protein and a polynucleotide sequence encoding a fusion protein of claim 20 under transcriptional control of one Promoter.

45. The use of an expression vector of claim 1 for the preparation of a medicament for inducing an immune response in a mammal comprising a polynucleotide sequence encoding a cytokine protein and a polynucleotide sequence encoding a fusion protein of claim 20, which are under separate transcriptional control, and wherein the polynucleotide sequence encoding the cytokine protein and the polynucleotide sequence encoding the fusion protein are in tandem in the one expression vector.

46. Use of two different retrogen expression vectors for the preparation of a medicament for inducing an immune response in a mammal, wherein the first and the second retrogen expression vector are independent vectors according to any of claims 1-16.

47. Use of an expression vector for the preparation of a medicament for inducing an immune response in a mammal, wherein said expression vector comprises a polynucleotide sequence encoding a first fusion protein of claim 20 and a polynucleotide sequence encoding a second fusion protein of claim 20 under transcriptional control of one promoter, wherein said first fusion protein comprises a first Signal sequence, a first antigen and a first cell binding element, which is an Fc fragment and said second fusion protein comprises a second Signal sequence, a second antigen and a second cell binding element, which is an Fc fragment.
48. The use of Claim 47, wherein said first and second Signal sequences are the same Signal sequence, first and second antigens are different antigens and said first and second cell binding elements are the same cell binding element.

49. The use of Claim 47, wherein said first and second Signal sequences are different Signal sequences, first and second antigens are different antigens and said first and second cell binding elements are the same cell binding element.

50. The use of Claim 47, wherein said first and second signal sequences are the same Signal sequence, first and second antigens are different antigens and said first and second cell binding elements are different cell binding elements.

51. The use of Claim 47, wherein said first and second Signal sequences are different Signal sequences, first and second antigens are different antigens, and said first and second cell binding elements are different cell binding elements.

52. The use of Claim 47, wherein the polynucleotide sequence encoding the first fusion protein and the polynucleotide sequence encoding the second fusion protein are under separate transcriptional control, and wherein the polynucleotide sequence encoding the first fusion protein and the polynucleotide sequence encoding the second fusion protein are in tandem in one expression vector.

53. Use of a fusion protein of claim 20 for the preparation of a medicament for simultaneously inducing both CD4+ and CD8+ T-cells, wherein the protein comprises both a MHC-I and MHC-II epitope fused to a cell binding element.

54. A method of producing a fusion protein comprising the steps of:

transducing an antigen presenting cell by introducing an expression vector of any of claims 1 to 16 into said antigen presenting cell to produce a transduced antigen presenting cell and expressing said vector to produce a fusion protein under conditions, wherein said fusion protein is secreted from the cell.

55. Use of the fusion protein of claim 20 for the preparation of a medicament for the treatment of a mammal, wherein the antigen presenting cells are transduced with the fusion protein in vitro prior to the administration of the medicament to said mammal.

56. Use of the fusion protein of claim 20 for the preparation of a medicament for the treatment of a mammal, wherein the fusion protein is to be administered parenterally to said mammal.

57. A method of secreting an intracellular protein comprising the steps of:

introducing an expression vector of any of claims 1-16 into a cell in vitro, and expressing said vector to produce a fusion protein under conditions, wherein said fusion protein is secreted from the cell.

58. The method of Claim 57, wherein a region of said polynucleotide encoding an intracellular protein is truncated to increase the efficiency of secretion.

59. The method of Claim 57, wherein a region of said polynucleotide encoding an intracellular protein is mutated to increase the efficiency of secretion.

60. A method as set out in Claim 57, wherein said polynucleotide encoding an intracellular protein is not a hepatitis B virus E antigen or a cancer antigen, which is MAGE-3, but HPV 16 E7.

61. A method of secreting a membrane protein comprising the steps of:

introducing an expression vector of any of claims 1 to 16 into a cell in vitro, and expressing said vector to produce a fusion protein under conditions, wherein said fusion protein is secreted from the cell.
62. The method of Claim 61, wherein a region of said polynucleotide encoding a membrane protein is truncated to increase the efficiency of secretion.

63. The method of Claim 61, wherein a region of said polynucleotide encoding a membrane protein is mutated to increase the efficiency of secretion.

64. A method as set out in Claim 61, wherein said polynucleotide encoding a membrane protein is not a hepatitis B virus E antigen or a cancer antigen, which is MAGE-3, but EBV nuclear antigen 1.

Patentansprüche

1. Ein Expressionsvektor, der eine Polynukleotid-Promotor-Sequenz umfasst, ein Polynukleotid, das eine Signal-Sequenz kodiert; einem Polynukleotid, das ein Antigen einer Infektionserkrankung kodiert, welches ein Hepatitis-B-Virus-E-Antigen ist oder ein Krebs-Antigen, das MAGE-3 ist, ein Polynukleotid, das ein Zellbindungselement kodiert sowie eine Polynukleotid-Polyadenylierungs-Sequenz, wobei alle operativ miteinander verbunden sind, wobei besagtes Polynukleotid, das ein Zell-Bindingselement kodiert, eine Polynukleotid-Sequenz ist eines Ligan-den, der an einen Zelloberflächenrezeptor bindet und besagte Polynukleotid-Sequenz eines Ligan-den ein Fc-Frag-ment ist.

2. Der Expressionsvektor gemäß Anspruch 1, wobei besagte Polynukleotid-Promotor-Sequenz ausgewählt ist aus der Gruppe bestehend aus einem konstitutiven Promotor, einem induzierbaren Promotor und einem gewebsspezifischen Promotor.


4. Der Expressionsvektor gemäß Anspruch 2, wobei besagter induzierbarer Promotor ausgewählt ist aus der Gruppe bestehend aus einem Metallothionin-Promotor, einem Glucocortikoid-Promotor, einem Progesteron-Promotor, und einem Tetracyclin-Promotor.

5. Der Expressionsvektor gemäß Anspruch 2, wobei der gewebsspezifische Promotor ausgewählt ist aus der Gruppe bestehend aus einem HER-2 Promotor und einem PSA-assozierten Promotor.


7. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Antigen kodiert, eine Polynukleotid-Sequenz umfasst für zumindest ein Epitop, wobei besagtes eine Epitop eine B-Zell-Antwort in einem Säu-getier induziert.

8. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Antigen kodiert, eine Polynukleotid-Sequenz umfasst für zumindest ein Epitop, wobei besagtes zumindest eine Epitop eine CD4+-T-Zell-Antwort in einem Säu-getier induziert.

9. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Antigen kodiert, eine Polynukleotid-Sequenz umfasst für zumindest ein Epitop, wobei besagtes zumindest eine Epitop eine CD8+-T-Zell-Antwort in einem Säu-getier induziert.

10. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Antigen kodiert, eine Polynukleotid-Sequenz umfasst, für zumindest ein Epitop, wobei besagtes zumindest eine Epitop eine B-Zell-Antwort induziert, eine CD4+-T-Zell-Antwort sowie eine CD8+-T-Zell-Antwort in einem Säugetier, in welchem besagtes Antigen eingeführt wird.
11. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Antigen kodiert, eine Polynukleotid-Sequenz für eine Vielzahl von Epitopen umfasst, wobei besagte Vielzahl von Epitopen eine B-Zell-Antwort induziert, eine CD4+ T-Zell-Antwort sowie eine CD8+ T-Zell-Antwort in einem Säugetier, in welches besagtes Antigen eingebracht wird.

12. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Zell-Bindungselement kodiert, ein homologes Fc-Fragment ist.

13. Der Expressionsvektor gemäß Anspruch 1, wobei besagtes Polynukleotid, das ein Zell-Bindungselement kodiert, ein heterologes Fc-Fragment ist.

14. Der Expressionsvektor gemäß Anspruch 1, wobei besagter Expressionsvektor des weiteren des weiteren eine Integrationssignal-Sequenz umfasst, die die Integration von besagtem Expressionsvektor in das Genom der Zelle ermöglicht.

15. Der Expressionsvektor gemäß Anspruch 14, wobei die Integrationssignal-Sequenz eine Virale Long Terminal repeat-Sequenz oder eine Adeno-assoziierte Virus-ITR-Sequenz ist.

16. Der Expressionsvektor gemäß Anspruch 1, wobei der Vektor ausgewählt ist aus der Gruppe bestehend aus einem viralen Vektor, einem bakteriellen Vektor und einem Säugetiervektor.

17. Eine isolierte transformierte Zelle umfassend einen Expressionsvektor gemäß irgendeinem der Ansprüche 1 bis 16, wobei besagter Expressionsvektor eine Polynukleo-tid-Promotor-Sequenz umfasst, ein Polynukleotid, das eine Signal-Sequenz kodiert, ein Polynukleotid, das ein Antigen kodiert, ein Polynukleotid, das ein Zell-Bindungselement kodiert, und eine Polynukleotid-Polyadenylierung-Sequenz, wobei alle operativ miteinander verknüpft sind.

18. Die Zelle gemäß Anspruch 17, wobei besagte Zelle prokaryontisch oder eukaryontisch ist.


20. Ein Fusionsprotein, das kodiert wird durch den Expressionsvektor gemäß irgendeinem der Ansprüche 1 bis 16.


25. Verwendung eines Expressionsvektors gemäß einem der Ansprüche 1 bis 16 zur Herstellung eines Medikaments zum Auslösen einer Immunantwort gerichtet gegen besagtes Antigen, wobei besagter Expressionsvektor für das Einbringen in eine Zelle ist und wobei besagte Zelle besagten Vektor exprimieren wird, um besagtes Antigen unter Bedingungen zu erzeugen, wobei besagtes Antigen sekretiert wird aus der Zelle; besagtes sekretiertes Antigen per Endocytose in die Zelle eingeschleust wird; besagtes per Endocytose eingeschleustes Antigen innerhalb der Zelle prozessiert wird; und besagtes prozessiertes Antigen auf einem Zelloberflächen-Protein präsentiert wird, um eine T-Zell-vermittelte Immunantwort auszulösen.

26. Verwendung gemäß Anspruch 25, wobei das prozessierte Antigen einem Zelloberflächen-Protein präsentiert wird, das ausgewählt ist aus der Gruppe bestehend aus MHC-I, MHC-II oder B-Zell-Rezeptoren.

27. Verwendung gemäß Anspruch 25, wobei das Antigen sekretiert wird durch eine erste Zelle und internalisiert wird durch eine zweite Zelle.

28. Verwendung gemäß Anspruch 27, wobei die erste Zelle und die zweite Zelle Antigen-präsentierende Zellen sind.
29. Verwendung gemäß Anspruch 27, wobei die erste Zelle eine nicht Antigen-präsentierende Zelle ist und die zweite Zelle eine Antigen-präsentierende Zelle ist.

30. Verwendung von Anspruch 29, wobei die erste Zelle eine Muskelzelle ist.

31. Verwendung eines Expressionsvektors gemäß Anspruch 1 für die Herstellung eines Medikaments zum Auslösen einer Immunantwort, gerichtet gegen ein Antigen in einem Säugetier, wobei das Medikament für die direkte Verabreichung von besagtem Säugetier auf parenteralem Weg ist.

32. Ein Verfahren zum Identifizieren einer Polynukleotid-Sequenz, welche zumindest ein MHC-II-begrenztes Epitop kodiert, das in der Lage ist, CD4+ Helfer-Zellen zu aktivieren, wobei besagtes Verfahren die folgenden Schritte umfasst:


33. Das Verfahren gemäß Anspruch 32, wobei das Polynukleotid, welches ein Testpolypeptid kodiert, eine cDNA-Bibliothek ist, die isoliert ist aus Tumor-Zelllinien.

34. Das Verfahren gemäß Anspruch 32, wobei das Polynukleotid, das ein Testpolypeptid kodiert, ausgewählt ist aus der Gruppe von cDNA-Bibliotheken bestehend aus viralen Genomen, bakteriellen Genomen, parasitären Genomen und menschlichen Genomen.

35. Ein Verfahren zum Identifizieren einer Polynukleotid-Sequenz, welche zumindest ein MHC-II-begrenztes Epitop kodiert, das in der Lage ist, eine Immunantwort in vivo auszulösen, wobei besagtes Verfahren die folgenden Schritte umfasst:

   Sammeln von T-Zellen aus Splenocyten in vitro aus einem Säugetier, an welches eine das transduzierte Antigen präsentierende Zelle verabreicht worden war, auf parenteralem Weg, wobei die das transduzierte Antigen präsentierende Zelle erzeugt worden ist durch Einbringen eines Expressionsvektors gemäß irgendeinem der Ansprüche 1 bis 16, in welchem das Polynukleotid, das ein Antigen kodiert, ersetzt ist durch ein Polynukleotid, das nicht bekannt ist, eine Immunantwort auszulösen, in Antigen-präsentierende Zellen in vitro und Co-Kultivieren von besagten T-Zellen mit dendritischen Zellen; und Bewertens der Aktivierung von T-Zellen, wobei besagte Aktivierung von T-Zellen anzeigt, dass das Polynukleotid, das das Testpolypeptid kodiert, eine Polynukleotid-Sequenz oder ein Fragment davon ist, das zumindest ein MAC-II-begrenztes Epitop kodiert, das in der Lage ist, CD4+-Helfer-T-Zellen zu aktivieren.

36. Ein Verfahren zum Identifizieren einer Polynukleotid-Sequenz, das zumindest ein MHC-II-begrenztes Epitop kodiert, das in der Lage ist, eine Immunantwort in vivo auszulösen, wobei besagtes Verfahren folgende Schritte umfasst:

   Sammeln von T-Zellen aus Splenocyten in vitro aus einem Säugetier, an welches ein Expressionsvektor gemäß irgendeinem der Ansprüche 1 bis 16, in welchem das Polynukleotid, das ein Antigen kodiert, ersetzt worden ist, durch ein Polynukleotid, von dem nicht bekannt ist, dass es eine Immunantwort auslöst, verabreicht worden war, auf parenteralem Weg, und Co-Kultivieren von besagtem T-Zellen mit dendritischen Zellen; und Bewertens der Aktivierung von T-Zellen, wobei besagte Aktivierung von T-Zellen anzeigt, dass das Polynukleotid, das das Test-Polypeptid kodiert, eine Polynukleotid-Sequenz oder ein Fragment davon ist, das zumindest ein MHC-II begrenztes Epitop kodiert, das in der Lage ist, CD4+-Helfer-T-Zellen zu aktivieren.

37. Das Verfahren gemäß irgendeinem der Ansprüche 35 und 36, wobei das Polynukleotid, das ein Test-Polypeptid kodiert, eine cDNA-Bibliothek ist, isoliert aus Tumor-Zelllinien.
38. Das Verfahren gemäß irgendeinem der Ansprüche 35 und 36, wobei das Polynukleotid, das ein Test-Polypeptid kodiert, ausgewählt ist aus der Gruppe von cDNA-Bibliotheken, die aus viralen Genomen bestehen, aus bakteriellen Genomen, parasitären Genomen und menschlichen Genomen.

39. Ein Verfahren zum Erzeugen eines Vakzins zur Immunisierung eines Säugetieres, umfassend die Schritte von:

\[ \text{in vitro Transduzieren von Antigen-präsentierenden Zellen durch Einbringen eines Expressionsvektors gemäß irgendeinem der Ansprüche 1 bis 16 in besagte Antigen-präsentierende Zellen, um eine transduzierte Antigen-präsentierende Zelle zu erzeugen, alle operativ verknüpft; und} \]

\[ \text{Exprimieren von besagtem Vektor, um ein Antigen zu erzeugen unter Bedingungen, in welchem besagtes Antigen von der Zelle sekretiert wird.} \]

40. Verwendung eines Vakzins gemäß irgendeinem der Ansprüche 21 bis 24 zum Transduzieren von Antigen-präsentierenden Zellen \textit{in vitro}.

41. Verwendung eines Cytokin-Expressionsvektors und des Retrogen-Expressionsvektors von Anspruch 1 für die Herstellung eines Medikamentes zum Induzieren einer Immunantwort ein einem Säugetier.

42. Verwendung gemäß Anspruch 41, wobei der Cytokin-Expressionsvektor die Sequenz für GM-CSF enthält.

43. Die Verwendung von Anspruch 41, wobei der Cytokin-Expressionsvektor die Sequenz für IL-2 enthält.

44. Verwendung eines Expressionsvektors für die Herstellung eines Medikaments für die Herstellung eines Medikaments zum Einbringen einer Immunantwort in ein Säugetier, wobei besagter Expressionsvektor eine Polynukleotid-Sequenz umfasst, die ein Cytokin-Protein kodiert, sowie eine Polynukleotid-Sequenz, die ein Fusionsprotein kodiert gemäß Anspruch 20, und zwar unter transkriptioneller Kontrolle von einem Promotor.

45. Die Verwendung eines Expressionsvektors gemäß Anspruch 1 für die Herstellung eines Medikaments zum Induzieren einer Immunantwort in einem Säugetier, umfassend eine Polynukleotid-Sequenz, die ein Cytokin-Protein kodiert und eine Polynukleotid-Sequenz, die ein Fusionsprotein gemäß Anspruch 20 kodiert, die unter separater transkriptioneller Steuerung sind, und wobei die Polynukleotid-Sequenz, die das Cytokin-Protein kodiert und die Polynukleotid-Sequenz, die das Fusionsprotein kodiert, in Tandem in dem einen Expressionsvektor vorliegen.

46. Verwendung von zwei unterschiedlichen Retrogen-Expressionsvektoren für die Herstellung eines Medikaments zum Induzieren einer Immunantwort in einem Säugetier, wobei der erste und der zweite Retrogen-Expressionsvektor unabhängige Vektores sind gemäß irgendeinem der Ansprüche 1 bis 16.

47. Verwendung eines Expressionsvektors für die Herstellung eines Medikaments zum Induzieren einer Immunantwort in einem Säugetier, wobei besagter Expressionsvektor eine Polynukleotid-Sequenz umfasst, der ein erstes Fusionsprotein kodiert gemäß Anspruch 20, sowie eine Polynukleotid-Sequenz, die ein zweites Fusionsprotein gemäß Anspruch 20 kodiert unter der transkriptionellen Kontrolle eines Promoters, wobei besagtes erstes Fusionsprotein eine erste Signal-Sequenz umfasst, ein erstes Antigen und ein erstes Zellbindungselement, das ein Fc-Fragment ist, und besagtes zweites Fusionsprotein eine zweite Signal-Sequenz umfasst, ein zweites Antigen und ein zweites Zellbindungselement, das ein Fc-Fragment ist.


51. Verwendung gemäß Anspruch 47, wobei besagte erste und zweite Signal-Sequenz unterschiedliche Signal-Se-
52. Die Verwendung gemäß Anspruch 47, wobei die Polynukleotid-Sequenz, die das erste Fusionsprotein kodiert und die Polynukleotid-Sequenz, die das zweite Fusionsprotein kodiert, unter separater transkriptioneller Kontrolle sind und wobei die Polynukleotid-Sequenz, die das erste Fusionsprotein kodiert und die Polynukleotid-Sequenz, die das zweite Fusionsprotein kodiert, in Tandem in einem Expressionsvektor vorliegen.

53. Verwendung eines Fusionsproteins gemäß Anspruch 20 für die Herstellung eines Medikaments zur gleichzeitigen Induktion sowohl von CD4+ als auch CD8+ T-Zellen, wobei das Protein sowohl ein MHC-I und ein MHC-II-Epitop umfasst, fusioniert an ein Zell-Bindungselement.

54. Ein Verfahren zum Herstellen eines Fusionsproteins umfassend die Schritte von:

Transduzieren einer Antigen-präsentierenden Zelle durch Einbringen eines Expressionsvektors gemäß irgendeinem der Ansprüche 1 bis 16 in besagte Antigen-präsentierende Zelle, um eine transduzierte Antigen-präsentierende Zelle zu erzeugen und Exprimieren von besagtem Vektor, um ein Fusionsprotein zu erzeugen unter Bedingungen, wobei besagtes Fusionsprotein aus der Zelle sekretiert wird.

55. Verwendung des Fusionsproteins gemäß Anspruch 20 für die Herstellung eines Medikaments für die Behandlung eines Säugetiers wobei die Antigen-präsentierenden Zellen transduziert werden mit dem Fusionsprotein in vitro vor der Verabreichung des Medikamentes an besagtes Säugetier.

56. Verwendung des Fusionsproteines gemäß Anspruch 20 für die Herstellung eines Medikaments für die Behandlung eines Säugetiers, wobei das Fusionsprotein parenteral an besagtes Säugetier verabreicht werden soll.

57. Ein Verfahren zum Sekretieren eines intrazellulären Proteins umfassend die folgenden Schritte:

Einbringen eines Expressionsvektors gemäß irgendeinem der Ansprüche 1 bis 16 in eine Zelle in vitro und Exprimieren von besagtem Vektor, um ein Fusionsprotein zu erzeugen unter Bedingungen, in welchen das Fusionsprotein aus der Zelle sekretiert wird.

58. Das Verfahren gemäß Anspruch 57, wobei eine Region von besagtem Polynukleotid, die ein intrazelluläres Protein kodiert, trunkiert ist, um die Effizienz der Sekretion zu erhöhen.

59. Das Verfahren gemäß Anspruch 57, wobei eine Region von besagtem Polynukleotid, das ein intrazelluläres Protein kodiert, mutiert ist, um die Effizienz der Sekretion zu erhöhen.

60. Ein Verfahren, wie in Anspruch 57 dargestellt, wobei besagtes Polynukleotid, das ein intrazelluläres Protein kodiert, nicht ein Hepatitis-B Virus-E-Antigen, oder ein Krebs-Antigen ist, das MAGE-3 ist, sondern HPV 16 E7.

61. Ein Verfahren zum Sekretieren eines Membran-Proteins, umfassend die Schritte von:

in vitro Einbringen eines Expressionsvektors von irgendeinem der Ansprüche 1 bis 16 in eine Zelle und Exprimieren von besagtem Vektor, um ein Fusionsprotein zu erzeugen unter Bedingungen, in welchem besagtes Fusionsprotein von der Zelle sekretiert wird.

62. Das Verfahren gemäß Anspruch 61, wobei eine Region von besagtem Polynukleotid, das ein Membranprotein kodiert, trunkiert ist, um die Effizienz der Sekretion zu erhöhen.

63. Das Verfahren gemäß Anspruch 61, wobei eine Region von besagtem Polynukleotid, die ein Membranprotein kodiert, mutiert ist, um die Effizienz der Sekretion zu erhöhen.

64. Ein Verfahren, wie in Anspruch 61 dargestellt, wobei besagtes Polynukleotid, das ein Membranprotein kodiert, nicht ein Hepatitis-B Virus-E-Antigen oder ein Krebs-Antigen ist, das MAGE-3 ist, sondern EBV-Nuklear Antigen 1.
Revendications

1. Vecteur d'expression comprenant une séquence promoteur polynucléotidique, un polynucléotide codant pour une séquence signal, un polynucléotide codant pour un antigène de maladie infectieuse qui est l’antigène E associé au virus de l’hépatite B ou un antigène cancérogène qui est le MAGE-3, un polynucléotide codant pour un élément de liaison cellulaire, et une séquence de polyadénylation polynucléotidique, tous liés activement, dans lequel le dit polynucléotide codant pour un élément de liaison cellulaire est une séquence polynucléotidique d’un ligand qui se lie à un récepteur de surface cellulaire et ladite séquence polynucléotidique d’un ligand est un fragment Fc.

2. Vecteur d’expression suivant la revendication 1, dans lequel ladite séquence promoteur polynucléotidique est choisie dans le groupe comprenant un promoteur constitutif, un promoteur inductible et un promoteur spécifique de tissu.


4. Vecteur d’expression suivant la revendication 2, dans lequel le promoteur inductible précité est choisi dans le groupe comprenant un promoteur de la métallothionine, un promoteur de glucocorticoïde, un promoteur de la progesterone et un promoteur de la tétracycline.

5. Vecteur d’expression suivant la revendication 2, dans lequel le promoteur spécifique de tissu précité est choisi dans le groupe comprenant le promoteur HER-2 et un promoteur associé au PSA.

6. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour une séquence signal est choisi dans le groupe comprenant une séquence signal de l’antigène E du virus de l’hépatite B, une séquence de tête des chaînes lourdes d’immunoglobulines et une séquence de tête de cytokine.

7. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un antigène comprend une séquence polynucléotidique pour au moins un épitope, dans lequel au moins ledit épitope induit une réponse aux cellules B chez un mammifère.

8. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un antigène comprend une séquence polynucléotidique pour au moins un épitope, dans lequel au moins ledit épitope induit une réponse aux cellules T CD4+ chez un mammifère.

9. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un antigène comprend une séquence polynucléotidique pour au moins un épitope, dans lequel au moins ledit épitope induit une réponse aux cellules T CD8+ chez un mammifère.

10. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un antigène comprend une séquence polynucléotidique pour une pluralité d’épitopes, dans lequel ladite pluralité d’épitopes induit une réponse aux cellules B, une réponse aux cellules T CD4+ et une réponse aux cellules T CD8+ chez un mammifère dans lequel ledit antigène est introduit.

11. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un antigène comprend une séquence polynucléotidique pour une pluralité d’épitopes, dans lequel ladite pluralité d’épitopes induit une réponse aux cellules B, une réponse aux cellules T CD4+ et une réponse aux cellules T CD8+ chez un mammifère dans lequel ledit antigène est introduit.

12. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un élément de liaison cellulaire est un fragment Fc homologue.

13. Vecteur d’expression suivant la revendication 1, dans lequel le polynucléotide précité codant pour un élément de
liaison cellulaire est un fragment Fc hétérologue.

14. Vecteur d’expression suivant la revendication 1, dans lequel ledit vecteur d’expression comprend de plus une séquence signal d’intégration qui facilite l’intégration dudit vecteur d’expression dans le génome de la cellule.

15. Vecteur d’expression suivant la revendication 14, dans lequel la séquence signal d’intégration est une séquence de longues séquences répétées virale ou une séquence ITR virale adéno-associée.

16. Vecteur d’expression suivant la revendication 1, dans lequel le vecteur est choisi dans le groupe comprenant un vecteur viral, un vecteur bactérien et un vecteur mammifère.

17. Cellule transformée isolée comprenant un vecteur d’expression suivant l’une quelconque des revendications 1 à 16, dans laquelle le dit vecteur d’expression comprend une séquence promoteur polynucléotidique, un polynucléotide codant pour une séquence signal, un polynucléotide codant pour un antigène, un polynucléotide codant pour un élément de liaison cellulaire et une séquence de polyadénylation polynucléotidique, tous liés activement.

18. Cellule suivant la revendication 17, dans laquelle ladite cellule est procaryotique ou eucaryotique.

19. Cellule suivant la revendication 18, dans laquelle ladite cellule eucaryotique est choisie dans le groupe comprenant les cellules eucaryotiques consistant en des cellules de levure, d’insectes et de mammifères.

20. Protéine de fusion codée par le vecteur d’expression suivant l’une quelconque des revendications 1 à 16.

21. Vaccin comprenant un vecteur d’expression suivant l’une quelconque des revendications 1 à 16.

22. Vaccin comprenant des cellules présentant l’antigène, dans lequel lesdites cellules présentant l’antigène sont transduites in vitro avec la protéine de fusion suivant la revendication 20.

23. Vaccin comprenant des cellules présentant l’antigène, dans lequel lesdites cellules présentant l’antigène sont transduites in vitro avec le vecteur d’expression suivant l’une quelconque des revendications 1 à 16.

24. Vaccin comprenant la protéine de fusion suivant la revendication 20.

25. Utilisation d’un vecteur d’expression suivant une séquence des revendications 1-16, pour la préparation d’un médicament pour déclencher une réponse immunitaire dirigée contre l’antigène précité, dans laquelle le dit vecteur d’expression est destiné à être introduit dans une cellule, et dans laquelle ladite cellule exprimera le dit vecteur pour produire le dit antigène sous des conditions, dans lesquelles le dit antigène est sécrété de la cellule, le dit antigène sécrété est endocytosé dans la cellule, le dit antigène endocytosé est traité à l’intérieur de la cellule, et le dit antigène traité est présenté à une protéine de surface cellulaire, pour déclencher une réponse immunitaire assurée par la médiation de cellules T.

26. Utilisation suivant la revendication 25, dans laquelle l’antigène traité est présenté à une protéine de surface cellulaire choisie dans le groupe comprenant le CMH-I, le CMH-II et les récepteurs de cellules B.

27. Utilisation suivant la revendication 25, dans laquelle l’antigène est sécrété par une première cellule et endocytosé par une seconde cellule.


29. Utilisation suivant la revendication 27, dans laquelle la première cellule est une cellule ne présentant pas l’antigène et la seconde cellule est une cellule présentant l’antigène.

30. Utilisation suivant la revendication 29, dans laquelle la première cellule est une cellule musculaire.

31. Utilisation d’un vecteur d’expression suivant la revendication 1 pour la préparation d’un médicament pour déclencher une réponse immunitaire dirigée contre un antigène chez un mammifère, dans laquelle le médicament est destiné à être administré directement audit mammifère via une voie parentérale.
32. Procédé d’identification d’une séquence polynucléotidique qui code pour au moins un épitope restreint par le CMH-II qui peut activer des cellules T auxiliaires CD4+, ledit procédé comprenant les étapes de :

- introduction in vitro d’un vecteur d’expression suivant l’une quelconque des revendications 1 à 16, dans lequel le polynucléotide codant pour un antigène est remplacé par un polynucléotide qui n’est pas connu comme déclenchant une réponse immunitaire, dans une cellule présentant l’antigène ;
- mise en contact de ladite cellule présentant l’antigène transduite avec des cellules T naïves ou des cellules T sensibilisées ; et
- détermination si les éventuelles cellules T naïves ou cellules T sensibilisées sont activées lors de la mise en contact avec ladite cellule présentant l’antigène transduite dans lequel l’activation desdites cellules T indique que le polynucléotide codant pour le polypeptide testé est un gène ou fragment de celui-ci, qui code pour au moins un épitope restreint par le CMH-II qui peut activer les cellules T auxiliaires CD4+.

33. Procédé suivant la revendication 32, dans lequel le polynucléotide codant pour un polypeptide testé est une bibliothèque d’ADNc isolée de lignées cellulaires tumorales.

34. Procédé suivant la revendication 32, dans lequel le polynucléotide codant pour un polypeptide testé est choisi dans le groupe comprenant les bibliothèques d’ADNc se composant de génomes viraux, de génomes bactériens, de génomes parasitaires et de génomes humains.

35. Procédé d’identification d’une séquence polynucléotidique qui code pour au moins un épitope restreint par le CMH-II qui peut déclencher une réponse immunitaire in vivo, ledit procédé comprenant les étapes de :

- collecte de cellules T de splénocytes in vitro d’un mammifère auquel une cellule présentant l’antigène transduite a été administrée via une voie parentérale, dans lequel la cellule représentant l’antigène transduite a été produite par introduction d’un vecteur d’expression suivant l’une quelconque des revendications 1 à 16, dans lequel le polynucléotide codant pour un antigène est remplacé par un polynucléotide qui n’est pas connu comme déclenchant une réponse immunitaire, dans des cellules présentant l’antigène in vitro, et de culture conjointe desdites cellules T avec des cellules dendritiques ; et
- détermination de l’activation de cellules T, dans lequel ladite activation des cellules T indique que le polynucléotide codant pour le polypeptide testé est une séquence polynucléotidique ou un fragment de celle-ci, qui code pour au moins un épitope restreint par le CMH-II qui peut activer des cellules T auxiliaires CD4+.

36. Procédé d’identification d’une séquence polynucléotidique qui code pour au moins un épitope restreint par le CMH-II qui peut déclencher une réponse immunitaire in vivo, ledit procédé comprenant les étapes de :

- collecte de cellules T de splénocytes in vitro d’un mammifère auquel un vecteur d’expression suivant l’une quelconque des revendications 1 à 16, dans lequel le polynucléotide codant pour un antigène est remplacé par un polynucléotide qui n’est pas connu comme déclenchant une réponse immunitaire, avait été administré via une voie parentérale et culture conjointe desdites cellules T avec des cellules dendritiques ; et
- détermination de l’activation de cellules T, dans lequel ladite activation des cellules T indique que le polynucléotide codant pour le polypeptide testé est une séquence polynucléotidique ou un fragment de celle-ci, qui code pour au moins un épitope restreint par le CMH-II qui peut activer des cellules T auxiliaires CD4+.

37. Procédé suivant l’un ou l’autre des revendications 35 et 36, dans lequel le polynucléotide codant pour un polypeptide testé est une bibliothèque d’ADNc isolée de lignées cellulaires tumorales.

38. Procédé suivant l’une ou l’autre des revendications 35 et 36, dans lequel le polynucléotide codant pour un polypeptide testé est choisi dans le groupe comprenant les bibliothèques d’ADNc se composant de génomes viraux, de génomes bactériens, de génomes parasitaires et de génomes humains.

39. Procédé de production d’un vaccin pour immuniser un mammifère comprenant les étapes de :

- transduction de cellules présentant l’antigène in vitro par introduction d’un vecteur d’expression suivant l’une quelconque des revendications 1-16 dans lesdites cellules présentant l’antigène pour produire une cellule présentant l’antigène transduite, tous liés activement ; et
- expression dudit vecteur pour produire un antigène sous des conditions dans lesquelles ledit antigène est sécrété de la cellule.

41. Utilisation d’un vecteur d’expression de cytokine et du vecteur d’expression rétrogénérique suivant la revendication 1 pour la préparation d’un médicament pour induire une réponse immunitaire chez un mammifère.

42. Utilisation suivant la revendication 41, dans laquelle le vecteur d’expression de cytokine contient la séquence pour GM-CSF.

43. Utilisation suivant la revendication 41, dans laquelle le vecteur d’expression de cytokine contient la séquence pour IL-2.

44. Utilisation d’un vecteur d’expression pour la préparation d’un médicament pour induire une réponse immunitaire chez un mammifère, dans laquelle ledit vecteur d’expression comprend une séquence polynucléotidique codant pour une protéine de cytokine et une séquence polynucléotidique codant pour une protéine de fusion suivant la revendication 20 sous le contrôle transcriptionnel d’un promoteur.

45. Utilisation d’un vecteur d’expression suivant la revendication 1 pour la préparation d’un médicament pour induire une réponse immunitaire chez un mammifère comprenant une séquence polynucléotidique codant pour une protéine de cytokine et une séquence polynucléotidique codant pour une protéine de fusion suivant la revendication 20, qui sont sous un contrôle transcriptionnel séparé, et dans laquelle la séquence polynucléotidique codant pour la protéine de cytokine et la séquence polynucléotidique codant pour la protéine de fusion sont en tandem dans le seul vecteur d’expression.

46. Utilisation de deux vecteurs d’expression rétrogéniques différents pour la préparation d’un médicament pour induire une réponse immunitaire chez un mammifère, dans laquelle le premier et le second vecteur d’expression rétrogéniques sont des vecteurs indépendants suivant l’une quelconque des revendications 1-16.

47. Utilisation d’un vecteur d’expression pour la préparation d’un médicament pour induire une réponse immunitaire chez un mammifère, dans laquelle ledit vecteur d’expression comprend une séquence polynucléotidique codant pour une première protéine de fusion suivant la revendication 20 et une séquence polynucléotidique codant pour une seconde protéine de fusion suivant la revendication 20 sous le contrôle transcriptionnel d’un promoteur, dans laquelle ladite première protéine de fusion comprend une première séquence signal, un premier antigène et un premier élément de liaison cellulaire, qui est un fragment Fc et ladite seconde protéine de fusion comprend une seconde séquence signal, un second antigène et un second élément de liaison cellulaire, qui est un fragment Fc.

48. Utilisation suivant la revendication 47, dans laquelle lesdites première et seconde séquence signal sont la même séquence signal, le premier et le second antigène sont des antigènes différents et lesdits premier et second élément de liaison cellulaires sont le même élément de liaison cellulaire.

49. Utilisation suivant la revendication 47, dans laquelle lesdites première et seconde séquence signal sont des séquences signal différentes, le premier et le second antigène sont des antigènes différents et lesdits premier et second élément de liaison cellulaires sont le même élément de liaison cellulaire.

50. Utilisation suivant la revendication 47, dans laquelle lesdites première et seconde séquence signal sont la même séquence signal, le premier et le second antigène sont des antigènes différents et lesdits premier et second élément de liaison cellulaires sont des éléments de liaison cellulaires différents.

51. Utilisation suivant la revendication 47, dans laquelle lesdites première et seconde séquence signal sont des séquences signal différentes, le premier et le second antigène sont des antigènes différents, et lesdits premier et second élément de liaison cellulaires sont des éléments de liaison cellulaires différents.

52. Utilisation suivant la revendication 47, dans laquelle la séquence polynucléotidique codant pour la première protéine de fusion et la séquence polynucléotidique codant pour la seconde protéine de fusion sont sous un contrôle transcriptionnel séparé, et dans laquelle la séquence polynucléotidique codant pour la première protéine de fusion et la séquence polynucléotidique codant pour la seconde protéine de fusion sont en tandem dans un seul vecteur d’expression.
53. Utilisation d’une protéine de fusion suivant la revendication 20 pour la préparation d’un médicament pour induire simultanément à la fois des cellules T CD4+ et CD8+, dans laquelle la protéine comprend à la fois un épitope de CMH-I et CMH-II fusionné à un élément de liaison cellulaire.

54. Procédé de production d’une protéine de fusion comprenant les étapes de :

transduction d’une cellule présentant l’antigène par introduction d’un vecteur d’expression suivant l’une quelconque des revendications 1 à 16 dans ladite cellule présentant l’antigène pour produire une cellule présentant l’antigène transduite, et

expression dudit vecteur pour produire une protéine de fusion sous des conditions, dans lesquelles ladite protéine de fusion est sécrétée de la cellule.

55. Utilisation de la protéine de fusion suivant la revendication 20 pour la préparation d’un médicament pour le traitement d’un mammifère, dans laquelle les cellules présentant l’antigène sont transduites avec la protéine de fusion in vitro avant l’administration du médicament audit mammifère.

56. Utilisation de la protéine de fusion suivant la revendication 20 pour la préparation d’un médicament pour le traitement d’un mammifère, dans laquelle la protéine de fusion est à administrer parentéralement audit mammifère.

57. Procédé de sécrétion d’une protéine intracellulaire comprenant les étapes de :

introduction d’un vecteur d’expression suivant l’une quelconque des revendications 1-16 dans une cellule in vitro, et

expression dudit vecteur pour produire une protéine de fusion sous des conditions, dans lesquelles ladite protéine de fusion est sécrétée de la cellule.

58. Procédé suivant la revendication 57, dans lequel une région dudit polynucléotide codant pour une protéine intracellulaire est tronquée pour accroître l’efficacité de sécrétion.

59. Procédé suivant la revendication 57, dans lequel une région dudit polynucléotide codant pour une protéine intracellulaire est mutée pour accroître l’efficacité de sécrétion.

60. Procédé tel que décrit dans la revendication 57, dans lequel ledit polynucléotide codant pour une protéine intracellulaire n’est pas un antigène E associé au virus de l’hépatite B ou un antigène cancérogène, qui est le MAGE-3, mais le HPV 16 E7.

61. Procédé de sécrétion d’une protéine membranaire comprenant les étapes de :

introduction d’un vecteur d’expression suivant l’une quelconque des revendications 1 à 16 dans une cellule in vitro, et

expression dudit vecteur pour produire une protéine de fusion sous des conditions, dans lesquelles ladite protéine de fusion est sécrétée de la cellule.

62. Procédé suivant la revendication 61, dans lequel une région dudit polynucléotide codant pour une protéine membranaire est tronquée pour accroître l’efficacité de sécrétion.

63. Procédé suivant la revendication 61, dans lequel une région dudit polynucléotide codant pour une protéine membranaire est mutée pour accroître l’efficacité de sécrétion.

64. Procédé tel que décrit dans la revendication 61, dans lequel ledit polynucléotide codant pour une protéine membranaire n’est pas un antigène E associé au virus de l’hépatite B ou un antigène cancérogène, qui est le MAGE-3, mais l’antigène nucléaire 1 de l’EBV.
Figure 2A
IL-5 for cell-binding (HbeAg, Hepatitis B Virus)

LNC-IL5-HBeAg  LTR ΔNGFR CMV S IL-S HBeAg LTR

LNC-IL-5  LTR ΔNGFR CMV S IL-S LTR

Fc fragment for Tyroninase (Melanoma)

LNC-TYR-Fc  LTR ΔNGFR CMV S TYR Fc LTR

LNC-TYR  LTR ΔNGFR CMV S TYR LTR

LNC-TYR  LTR ΔNGFR CMV TYR LTR

Fc fragment for Papillaomavirus 16 E-7 (Cervical cancer)

LNC-E7-Fc  LTR ΔNGFR CMV S E7 Fc LTR

LNC-S-E7  LTR ΔNGFR CMV S E7 LTR

LNC-E7  LTR ΔNGFR CMV E7 LTR

Figure 2B
PET Cell-binding domain for HIV-1

Figure 2C
Figure 3
Untransduced DCs
Figure 4A

Transduced DCs
Figure 4B

Negative Control
Figure 4C
Figure 6A

Figure 6B
Figure 7A

Figure 7B
Figure 9D

Figure 9E

Figure 9F
Figure 10A

Figure 10B

Figure 10C

Figure 10D
Figure 14
SEQ. ID. NO.: 19

MHGDTPTLHEYMMLDLQPETTD
LYCYEQLSDSSEEEDEIDGPAG
QAEPDRAHYNIVTFCCCKCDSTL
RLCVQSTHDIRTLEDLLMGTL
GIVCPICSQKPL

FIGURE 17
FIGURE 18
Figure 22

- HBeFc/EL-4-HBcAg
- HBcAg/EL4-HBcAg
- HBeAg/EL4-HBcAg
- Fc/EL4-HBcAg
- HBeFc/EL4-MAGE3

Specific Killing %

E:T=100:1  E:T=3:1
Figure 25
Figure 26
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 13275299 P [0001]
- US 13275099 P [0001]
- US 4683202 A [0111]
- US 5928906 A [0111]
- US 5871986 A [0133]
- US 4879236 A [0133]
- US 5399346 A [0142]
- US 5925565 A [0156]
- US 5871986 A [0156]
- US 4082735 A [0168]
- US 4082736 A [0168]
- US 4101536 A [0168]
- US 4185089 A [0168]
- US 4235771 A [0168]
- US 4406890 A [0168]
- US 4606918 A [0168]
- US 5220007 A [0250]
- US 5284760 A [0250]
- US 5354670 A [0250]
- US 5366878 A [0250]
- US 5389514 A [0250]
- US 5635377 A [0250]
- US 5789166 A [0250]
- US 60132752 B [0262]
- US 60132750 B [0262]

Non-patent literature cited in the description

- DRUG CARRIERS IN BIOLOGY AND MEDICINE. 1979, 287-341 [0195]
- THUS ; SIDERS ; MIZEL. J. Biol. Chem., 1995 [0251]
- DAERON, M. Annual Review of Immunology, 1997, vol. 15, 203-34 [0261]
- Liposome Preparation: Methods and Mechanisms. DEAMER ; USTER. LIPOSOMES. 1983 [0261]
- Methods for General and Molecular Bacteriology. American Society for Microbiology, 1994 [0261]
- GHOSH ; BACHHAWAT. Liver diseases, targeted diagnosis and therapy using specific receptors and ligands. Marel Dekker, 1991, 87-104 [0261]
- GREGORIADIS. DRUG CARRIERS IN BIOLOGY AND MEDICINE. 1979, 287-341 [0261]


• STEINMAN, R.M.; SWANSON, J. J. of Experimental Medicine, 1995, vol. 182, 283-8

• SYRENGELAS, A.D.; LEVY, R. J. of Immunology, 1999, vol. 162, 4790-5


• VAN DEN EYnde, B.J.; VAN DER BRUGGEN, P. Current Opinion in Immunology, 1997, vol. 9, 684-93


• WATTS, C. Annual Review of Immunology, 1997, vol. 15, 821-50


